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Abstract: Background: The airway epithelium is exposed to a range of physical and chemical irritants in 
the environment which are known to trigger asthma. Transient Receptor Potential (TRP) cation 
channels play a central role in sensory responses to noxious physical and chemical stimuli. Recent 
genetic evidence suggests an involvement of TRPV1, one member of the vanilloid subfamily of TRP 
channels, in the pathophysiology of asthma. The functional expression of TRPV1 on airway epithelium 
has yet to be elucidated.    
Objective: In this study we examined the molecular, functional and immunohistochemical expression of 
TRPV1 in the asthmatic and healthy airway.  
Methods: Bronchial biopsies and bronchial brushings were obtained from healthy volunteers (n=18), 
mild to moderate asthmatics (n=24) and refractory asthmatics (n=22). To investigate the functional 
role of TRPV1, cultured primary bronchial epithelial cells (PBEC) from mild asthmatics (n=4), non 
asthmatic coughers (n=4) and healthy subjects (n=4) were studied. 
Results: Quantitative immunohistochemistry revealed significantly more TRPV1 expression in 
asthmatics compared to healthy subjects and with greatest expression in the refractory asthmatics 
(p=0.001). PCR and Western blotting analysis confirmed gene and protein expression of TRPV1 in 
cultured primary bronchial epithelial cells (PBEC). Patch-clamp electrophysiology directly confirmed 
functional TRPV1 expression in all three groups. In functional assays, the TRPV1 agonist capsaicin 
induced dose dependent interleukin-8 (IL-8) release which could be blocked by the antagonist 
capsazepine. Reduction of external pH from 7.4 to 6.4 activated a capsazepine-sensitive outwardly-
recifiying membrane current. 
 
Conclusions: Functional TRPV1 channels are present in the human airway epithelium and are over-
expressed in the airways of refractory asthmatics. These channels may represent a novel therapeutic 
target for uncontrolled asthma.  
 
 
 
 
 
 
 
Dr Lorcan McGarvey 
Centre for Infection & Immunity 
Health Sciences Building 
Queen’s University Belfast 
97 Lisburn Road, Belfast 
BT9 7BL,  
N Ireland 
 
To The Editors 
Journal of Allergy and Clinical Immunology 
 
15th August 2013 
 
Dear Editors, 
 
 
Many thanks for the opportunity to respond to the reviewers comments and to 
submit a revised manuscript. We found each of the comments extremely helpful 
and based on these have undertaken a number of additional experiments which we 
and believe have resulted in an improved manuscript. We have provided our 
response to the specific comments from the Editor and each of the reviewers’ 
comments below and indicated where changes have been made to the manuscript 
 
SPECIFIC COMMENTS FROM THE EDITOR: 
Although your submission is intriguing, there are issues regarding specificity 
of the cell types studied, sample size for some of the assessments, and 
examination of the impact of leukotrienes; these must be addressed. 
 
RESPONSE: We are pleased that the Editor finds our manuscript intriguing. We 
have undertaken additional experiments to address the issue regarding cell 
specificity and addressed the important issue of studying more specific 
environmental irritants in particular the effect of acidic pH. We have also 
considered and responded to the comment regarding leukotrienes.  
We have also reduced the length of article to meet with the request to 
restrict length to 7 pages and reduced the figure legend word count where 
possible to fewer than 60 words.  
 
COMMENTS FROM REVIEWER #1:  
General Comments 
I thought that the methodology was sound in this manuscript. My major 
questions center on following numbers of subjects done for each assay, which 
made the manuscript more difficult to follow.  
 
RESPONSE: We thank the reviewer for this positive comment and we are pleased 
they believe our methodology to be ‘sound’. We have carefully addressed each 
of the specific comments below to provide clarification on ‘number of subjects 
done for each assay’.  
 
Specific Comments 
1) It is unclear why there are two separate cohorts of patients---the 
Belfast and Leicester. I was unclear how many from each group had IHC 
and gene expression assays. Did the same subjects have microarray, qPCR 
and IHC, or did only the Leicester cohort have microarray and the IHC 
Responses to Comments
was done from subjects from Belfast---this was difficult to follow in 
the manuscript. 
  
RESPONSE: We apologise for the lack of clarity. IHC was performed on the 
Belfast Cohort only and the microarray and qPCR was performed only on the 
freshly isolated brushings from Leicester cohort. We have now clarified this 
in our methods section and have indicated the number of subjects (see methods 
section revised manuscript (Marked), page 8, line 17-20) 
 
2) How were subjects with possible COPD excluded? In table 1, the pack 
year range was 1-20 years. Or does it not matter that this group with 
severe asthma may have included not "pure asthma."  
 
RESPONSE: Data from this cohort has been published previously. (Shikotra A et 
al. Increased expression of immunoreactive thymic stromal lymphopoietin in 
patients with severe asthma. J Allergy Clin Immunol. 2012 Jan;129(1):104-11 
and Butler CA et al. Glucocorticoid receptor β and histone deacetylase 1 and 2 
expression in the airways of severe asthma. Thorax. 2012 May;67(5):392-8). A 
great strength of the cohort is that the patients are well characterised in 
specialist centres with regard to diagnosis, physiology and adherence with 
therapy and all fulfil the definition of severe refractory asthma. The median 
pack year history is only 2.5 years and in an analysis of ex-smokers, we have 
also recently demonstrated that ex-smokers with a <10 pack year history have 
broadly similar demographic and inflammatory profiles to never smokers with 
severe asthma (Thomson NC et al. Clinical outcomes and inflammatory biomarkers 
in current smokers and ex-smokers with severe asthma. J Allergy Clin Immunol. 
2013 Apr;131(4):1008-16) and so we believe that the smoking history does not 
affect the conclusions from this study. 
 
3) Were subjects in Table 2 also included in Table 1? Table 2 also should 
read "mild asthma" instead of cough variant asthma to match the text. 
Also, why are the FEV1 and the FEV1/FVC lowest in the non-asthmatic 
coughers in Table 2?  
 
RESPONSE:  No, the subjects in table 2 were recruited from a specialist cough 
clinic and are not included in table 1. We have adjusted the text in table 2 
as recommended by this reviewer. Although the absolute FEV1 values are lower 
in non-asthmatic coughers the % predicted values are in fact higher. The 
FEV1/FVC ratios are lower in this group although still within normal limits 
and not likely to be clinical importance 
 
4) Why does Figure 1A only have a representative for normal subjects? Is 
the conclusion that TRPV1 also found in normal subjects? You have data 
from qPCR that TRPV1 does not differ from normals and asthmatics.  
 
RESPONSE: We undertook the experiments (represented in figure 1) to first 
establish that we could detect the presence of mRNA for the TRPV family of 
channels including TRPV1 in human bronchial epithelium. Once this was 
confirmed we undertook the subsequent sequence of experiments to examine 
expression of TRPV1 at protein level and its function and potential relevance 
to the asthmatic airway. We included this in the original manuscript to 
provide some chronology to our sequence of experiments. However we would be 
happy to remove this from the revised manuscript if this is felt to be 
preferable. 
  
5) What is the significance of the difference of TRPV1 expression by 
IHC/microarray (i.e., increased with more severe asthma) and then no 
difference between groups in relationship to function.  
 
RESPONSE: We thank the reviewer for pointing out this interesting observation. 
The functional findings described in this manuscript (i.e. IL-8 release in 
response to TRPV1 activation by capsaicin) represent just one consequence of 
TRPV1 activation. The lack of difference may reflect sample size and we have 
commented on this issue in our revised marked manuscript (page 14, line 11) 
 
 
COMMENTS FROM REVIEWER #2:  
The expression of TRPV1, a sensory cation channel was investigated in the 
airway epithelium of asthmatic patients. Quantitative assessment by 
immunohistochemistry showed significantly more TRPV1 expression in the 
epithelium of asthmatics when compared with healthy controls, with the highest 
expression measured in a group designated as "refractory asthmatics" by the 
authors. In vitro stimulation of TRPV1 by capsaicin induced IL-8 expression in 
epithelial cell cultures that was blocked by the antagonist capsazepine. The 
authors concluded that TRPV1 channels may represent a novel therapeutic target 
for uncontrolled asthma.  
 
General Comments 
1. While the study investigates an interesting question in regards to the 
function of TRPV1 on epithelial cells in the airways of asthmatic 
patients, the relevance of the demonstrated findings remain unclear and 
the conclusion is over stated. The authors aimed to investigate the 
effects of environmental irritants on TRPV1, but only capsaicin was 
used, which is not really an environmental irritant. It would support 
the claims if the effects of pH and temperature changes were studied in 
addition to capsaicin in epithelial cells.  
 
RESPONSE: We thank the reviewer for this very helpful comment. Based on these 
comments we have undertaken a series of additional experiments on our primary 
bronchial epithelial cells to evaluate the effect of lowering pH from 7.4 to 
6.4 on bronchial epithelial cell membrane currents. We observed large 
outwardly rectifying currents with typical TRPV1 signature at pH 6.4 which 
were abrogated with the TRPV1 antagonist capsazepine (see figures 1 and 2 
below). This important finding now provides evidence of a physiologically 
relevant environmental irritant (i.e. acid pH) activating membrane bound TRPV1 
channels on bronchial epithelial cells and is very supportive of our original 
hypothesis. In our revised manuscript we have detailed these additional 
experiments, described the results and commented on their significance within 
the discussion 
 
 
 
FIGURE 1                                  FIGURE 2 
 
 
2. The rationale and significance of the epithelial cells as opposed to 
other structural cells of the airways such as fibroblasts and smooth 
muscle cells is not supported convincingly. In their introduction the 
authors are creating the impression that coughing and wheezing to 
environmental irritants maybe due to TRPV expression on the epithelial 
cells. These responses are in fact directly due to activation of 
sensory neurons that lead to bronchospasm and coughing/wheezing. This 
needs to be clarified. 
 
RESPONSE: This is an important point raised by the reviewer. They are correct 
in pointing out that protective/irritant airway responses such as bronchospasm 
and cough are directly due to neuronal activation. However there is evidence 
that neuronal airway responses may be sensitized in disease such as asthma and 
we propose that activation of TRPV1 on non-neuronal cells (in this case 
bronchial epithelial cells) by irritants with subsequent release of 
sensitizing mediators represents one possible mechanism as to how this may 
arise. We have now revised our introduction to clarify this (see revised 
marked manuscript page 8, lines 1-4)   
 
Specific Comments 
3. What is the definition of "refractory asthmatics"? This is an important 
group of patients, and how it was defined needs to be spelled out more 
clearly.  
RESPONSE: As stated in the manuscript ‘….participants with refractory asthma 
were recruited from the Belfast City Hospital. All had persisting symptoms 
despite treatment at Step 4 or 5 of the Global Initiative for Asthma (GINA) 
guidelines….’. We have now added the following  ‘……fulfilled the ATS 
definition of refractory asthma (reference - Proceedings of the ATS workshop 
on refractory asthma. Current understanding, recommendations, and unanswered 
questions. American Journal of Respiratory and Critical Care Medicine. 
2000;162(6):2341-51) 
 
4. Was there any statistical correlation between asthma severity and the 
expression of TRPV1 (either in the mRNA or the protein expression?)  
RESPONSE: Although epithelial TRPV1 expression in the airway biopsies were 
significantly greater in asthma compared with health we found no statistical 
correlation between disease severity either defined by lung function, inhaled 
steroid dose (BDP equivalent) or oral steroid dose.  
 
5. Figure1A: The mRNA bands appear at different levels, what is the 
explanation for that? Why is there no band at V5? What are the V1-V6 
designations?  
RESPONSE: We apologise for not clarifying this and have now revised the legend 
accompanying figure 1. The V1-V6 designations represent the sub types of the 
TRPV (vanilloid) family, hence slightly different band levels. TRPV1 was the 
focus of interest in this manuscript but others (although not TRPV5) appear to 
be expressed in the samples we studied.    
 
6. Figure 1B: It appears that in lane 2 the 95kDa band is missing or is very 
faintly expressed. What is the explanation?  
 
RESPONSE: We believe the differences in band intensity represent differential 
expression of protein levels between samples. 
 
7. Figure 1C: In the microarray what was the control that the expression level 
is standardized to? It appears that all of the expression is below 1.  
 
RESPONSE: The gene expression microarrays were conducted as described 
previously in J Immunol 2011;186:1861-1869.  In brief, two color Agilent Whole 
Human Genome microarrays using a common reference design (utilizing Universal 
Human Reference RNA, Stratagene, La Jolla, CA for the reference channel) were 
employed in this study. Gene expression was calculated as the log2 ratio of 
test and reference channel values.  The reference sample facilitates array to 
array normalization as a technical control.  As a result, the expression 
values (log2 ratios) for a given gene will be arbitrarily offset based on the 
relative abundance of mRNA in the Human Reference RNA sample as compared to 
the test samples. 
 
8. In addition to the epithelium in Figures 2 and 3 there appears to be 
significant TRPV1 positivity in the submucosal area. This ought to be 
investigated by the authors, especially in regards to the proinflammatory 
significance as fibroblasts and smooth muscle cells are a prominent source of 
IL-8 and similar proinflammatory chemokines. 
 
RESPONSE:  This is an important comment from the reviewer. We agree that the 
role of other non-neuronal cells (e.g. smooth muscle cells) may play a role in 
TRPV1 mediated inflammatory response. Indeed we have undertaken some 
preliminary experiments which provides evidence to support this (please see 
our response below to the reviewers next comment). However we are keen to 
confine the focus of this current manuscript to the expression and function of 
TRPV1 in bronchial epithelial cells. We believe our findings in relation to 
the bronchial epithelium represent an interesting finding. We believe our 
preliminary experiments in primary smooth muscle cells will form the basis for 
future work. However if the Editor feels this would improve the manuscript we 
would be provide this preliminary data.  
 
 
9. Along the same line, it would be imperative to add experiments in which 
cultured fibroblast and smooth muscle cells are also investigated for their 
membrane potential and their expression of IL-8 in response to capsaicin 
stimulation.  
 
RESPONSE: We have undertaken some preliminary experiments to confirm that 
primary human airway smooth muscle cells (ASM) are activated by capsaicin to 
release IL-8 and this can be almost completely inhibited by the TRPV1 
antagonist capsazepine. ASM cells were treated for 24 hours with 10, 25 or 50 
μM capsaicin or control medium. Supernatants were collected after 24 h and 
ELISA was performed to measure the release of IL-8. (see figure 3 below). As 
indicated in our response above we believe these findings require an extensive 
programme of work which is outside the focus of our current manuscript. 
 
 
Figure3 Capsaicin induced IL-8 release from primary human airway smooth muscle 
cells 
 
10. The intracytoplasmic expression of the TRPV1 receptor expression is 
interesting and needs further experimental support. For example, co-
localization with endoplasmic reticulum markers would provide additional 
support. The functional significance of this TRPV1 as opposed to the membrane 
expressed molecule needs to be investigated.  
 
RESPONSE: As suggested by the reviewer we have now undertaken some additional 
immunolabelling experiments demonstrating that TRPV1 does co-localise with ER 
markers in bronchial epithelial cells (see figure 4 below). We have included 
this in our results (page 12, line 15-19) and discussion (page 16, line 7-10) 
section of our revised manuscript. These channels may play a role in ER-Ca2+ 
release, but to fully establish this would require an extensive programme of 
work involving the development of routine methods for measuring cytoplasmic 
and ER Ca2+ in PBECs as well as patch-clamp recording of ER membranes from 
these cells. Whilst such studies obviously lie beyond the scope and focus of 
the current work, we believe that our findings do provide an important basis 
for such studies in the future. 
 
 
 
 
 
Figure 4: TRPV1 and ER colocalisation in human bronchial epithelial cells. 
Representative confocal microscopy images (A-C) showing immunohistochemistry 
staining of bronchial epithelial cells positive for TRPV1 (A) and ER (B) 
markers. Co-localisation was evident when the images were merged (C; 
orange/yellow). DAPI stained blue nuclei (C). Scale bar = 100 μm. 
 
 
 
COMMENTS FROM REVIEWER #3:  
This paper presents strong evidence for the presence of the TRPV1 receptor in 
airway epithelium and suggestive evidence of the increase in its expression in 
asthma, particularly in severe asthma.  
 
RESPONSE: We are delighted this reviewer believes our paper provides ‘strong 
evidence for the presence of the TRPV1 receptor in airway epithelium’. We have 
addressed each of their comments below. 
 
My Comments 
1. The subjects with severe asthma were older, had higher IgE levels, and 
had a greater smoking history than others studied. Do the authors have 
any data on non-asthmatic smokers to separate this as a potential cause 
of the increase identified?  
 
RESPONSE: The age and demographic features of the severe refractory group is 
very typical of this group (Heaney LG et al. Refractory asthma in the UK: 
cross-sectional findings from a UK multicentre registry. Thorax. 2010 
Sep;65(9):787-94). As discussed above, we have also recently published a 
detailed analysis on smokers, never smokers and ex-smokers with severe asthma 
and some of the features alluded to by the Reviewer are again typical of this 
more severe group (Thomson NC et al. Clinical outcomes and inflammatory 
biomarkers in current smokers and ex-smokers with severe asthma. J Allergy 
Clin Immunol. 2013 Apr;131(4):1008-16). It is an intriguing possibility that 
that ex-smoking may potentially contribute to some of the ‘steroid resistant’ 
mechanisms, which defines this severe population and we discuss this in our 
previous manuscript. However, we would argue that whatever the mechanism, the 
fact that our patients are precisely characterised in this cohort with regard 
to diagnosis, physiology and adherence with asthma therapy does not alter the 
significance of the findings. 
 
2. The authors comment that TRPV1 receptors were identified in submucosal 
cells. To what degree could these cells have contributed to their 
findings of increased numbers of receptors and to increased activity in 
asthma?  
 
RESPONSE: This is an important point raised by this reviewer. It is likely 
that a number of other non-neuronal cells in addition to bronchial epithelial 
cells express functional TRPV1 receptors. In our response to one of the other 
reviewers (Reviewer #2) comments above, we have provided some preliminary 
evidence that this is the case for primary airway smooth muscle cells. However 
we believe this is outside of the scope of the current manuscript.  
 
3. The authors state that TRPV1 receptors respond to LTB4. It would be of 
interest to know whether other leukotriene mediators share this 
property as it would further the link between expression of asthma and 
the function of these receptors. 
 
RESPONSE: There is no current evidence that other leukotriene mediators (e.g. 
LTD4 or LTE4) directly activate TRPV1 in the same fashion as LTB4. However it 
is clear that other products of lipoxygenase (e.g. 15(s)-HETE) are potent 
TRPV1 agonists and as such represent additional mechanisms whereby 
inflammatory mediators relevant to asthma may modulate TRPV1 function. 
 
 
We hope this response and revised manuscript addresses the issues raised 
during the review process.  
 
With best wishes 
 
Yours Sincerely 
 
Lorcan McGarvey (on behalf of the authors) 
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Email: l.mcgarvey@qub.ac.uk ; Phone: +44 28 90 26 3821 Fax: +44 28 90 26 3879 1 
 2 
 3 
Phone: +44 28 90 26 3821 4 
Fax: +44 28 90 26 3879 5 
ABSTRACT (250 words) 6 
Background: The airway epithelium is exposed to a range of physical and chemical irritants 7 
in the environment which are known to trigger asthma. Transient Receptor Potential (TRP) 8 
cation channels play a central role in sensory responses to noxious physical and chemical 9 
stimuli. Recent genetic evidence suggests an involvement of TRPV1, one member of the 10 
vanilloid subfamily of TRP channels, in the pathophysiology of asthma. The functional 11 
expression of TRPV1 on airway epithelium has yet to be elucidated.    12 
Objective: In this study we examined the molecular, functional and immunohistochemical 13 
expression of TRPV1 in the asthmatic and healthy airway.  14 
Methods: Bronchial biopsies and bronchial brushings were obtained from healthy 15 
volunteers (n=18), mild to moderate asthmatics (n=24) and refractory asthmatics (n=22). To 16 
investigate the functional role of TRPV1, cultured primary bronchial epithelial cells (PBEC) 17 
from mild asthmatics (n=4), non asthmatic coughers (n=4) and healthy subjects (n=4) were 18 
studied. 19 
Results: Quantitative immunohistochemistry revealed significantly more TRPV1 expression 20 
in asthmatics compared to healthy subjects and with greatest expression in the refractory 21 
asthmatics (p=0.001). PCR and Western blotting analysis confirmed gene and protein 22 
Formatted: French (France)
5 
 
expression of TRPV1 in cultured primary bronchial epithelial cells (PBEC). Patch-clamp 1 
electrophysiology directly confirmed functional TRPV1 expression in all three groups. In 2 
functional assays, the TRPV1 agonist capsaicin induced dose dependent interleukin-8 (IL-8) 3 
release which could be blocked by the antagonist capsazepine. Reduction of external pH 4 
from 7.4 to 6.4 activated a capsazepine-sensitive outwardly-recifiying membrane current. 5 
 6 
Conclusions: Functional TRPV1 channels are present in the human airway epithelium and 7 
are over-expressed in the airways of refractory asthmatics. These channels may represent a 8 
novel therapeutic target for uncontrolled asthma.  9 
10 
6 
 
Clinical Implications (30 words) 1 
TRPV1 is a functional channel activated by physical and chemical irritants. We report its 2 
overexpression in asthmatic airway epithelium most notably in severe disease suggesting a 3 
role in uncontrolled asthma. 4 
Capsule summary (35 words) 5 
The Transient Receptor Potential vanilloid-1 (TRPV1) channel regulates responses to irritant 6 
stimuli. We report TRPV1 overexpression in asthmatic airway epithelium most notably in 7 
severe disease suggesting its potential as a therapeutic target for uncontrolled asthma. 8 
 9 
Key words: ion channel, sensory, asthma, irritant, chemical, exacerbation, cough 10 
Abbreviations: 11 
TRP - Transient Receptor Potential 12 
TRPV1 – Transient Receptor Potential Vanilloid-1 13 
GINA – Global Initiative for Asthma Guidelines 14 
PBEC – Primary bronchial epithelial cell 15 
qPCR – Quantitative real-time PCR 16 
GMA – glycol methacrylate 17 
18 
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INTRODUCTION 1 
During an exacerbation of asthma, the airways become hypersensitive and patients are 2 
often troubled with bouts of cough and wheeze following exposure to relatively innocuous 3 
stimuli such as aerosols, strong odours or changes in air temperature. The precise 4 
mechanism for this airway hypersensitivity is not known but upregulation of receptors 5 
responsible for sensing chemical and physical stimuli may be relevant. The recently 6 
described Transient Receptor Potential (TRP) proteins, a family of Ca2+ permeable non 7 
selective cation channels which sense a vast array of chemical and physical stimuli (1, 2), are 8 
believed to have an important role in the regulation of airway function in both health and 9 
disease (3, 4). Recent data has provided genetic evidence for the involvement of one 10 
subfamily member, TRP vanilloid 1 (TRPV1) in asthma pathophysiology (5).  11 
TRPV1 is activated by capsaicin (the pungent principle contained in hot chilli peppers) and 12 
inhaled capsaicin causes cough (6) and bronchospasm (7) in asthmatics. The airway 13 
inflammatory events which accompany an exacerbation of asthma include a rise in airway 14 
temperature (8), acidosis (9) and release of mediators derived from lipoxygenase 15 
metabolism of arachidonic acid (4, 10). TRPV1 is primarily recognised as a heat thermal 16 
sensor, but it is also readily activated by low extracellular pH (11, 12) and lipoxygenase 17 
products such as leukotriene B4. (13). TRPV1 receptors are expressed in several cell types in 18 
human airway including sensory neurones (14), smooth muscle cells (15) and epithelial cells 19 
from both the upper (16) and lower airway (17). As the bronchial epithelium has an 20 
important role in sensing and responding to noxious stimuli we hypothesised that TRPV1 is 21 
over expressed in the airway epithelium of asthmatics, in particular those with difficult-to-22 
8 
 
treat asthma. and that Further we considered that the inflammatory response following 1 
irritant activation of airway epithelial TRPV1 has a functional role imay contribute to 2 
heighted neuronal reflexes responsible for cough and bronchospasm in asthma.n 3 
asthmamay  pathogenesis and airway responses to environmental irritants.  4 
In this study, we examined both TRPV1 expression and function in human bronchial 5 
epithelium. In addition we provide evidence for the overexpression of TRPV1 in the airways 6 
of severe asthmatics compared to mild asthmatics and healthy subjects. Some of the results 7 
of these studies have been reported in abstract form (18). 8 
 9 
METHODS AND MATERIALS 10 
Full methodological details are provided in an online data repository 11 
Study Subjects 12 
Participants with refractory asthma were recruited from the Belfast City Hospital. All had 13 
persisting symptoms despite treatment at Step 4 or 5 of the Global Initiative for Asthma 14 
(GINA) guidelines. Mild to moderate asthmatics had a clinical diagnosis of asthma with a 15 
current history of recurrent wheezing and documented response to asthma medication. 16 
Bronchial biopsy samples from this Belfast cohort were analysed using 17 
immunohistochemistry (IHC).  For examination of in vivo gene expression of TRPV1 in airway 18 
epithelium an additional cohort of subjects from Leicester were recruited. Demographic 19 
details of both cohorts are shown in Table 1. To investigate the functional role of TRPV1, 20 
primary bronchial epithelial cell (PBEC) cultures were grown from bronchial brushings 21 
9 
 
obtained from mild asthmatics and non-asthmatic patients recruited from a specialist cough 1 
clinic (19) and healthy participants recruited by advertisement. Demographic details are 2 
shown in Table 2.  3 
The study was approved by the appropriate Institutional Research Ethics Committees (details in 4 
online data repository). Written informed consent was gained from all participants prior to their 5 
involvement.  6 
 7 
 Bronchoscopy and sample processing 8 
All asthmatic participants were clinically stable at the time of bronchoscopy, and had an 9 
FEV1 >60% predicted. Bronchial biopsies and brushings were obtained from segmental 10 
airways using a standard techniques. Three biopsies from each participant (Belfast Cohort) 11 
were submitted for immunohistochemistry studies. Gene expression microarray analysis 12 
(and qPCR) was performed on fresh bronchial brushings (Leicester cohort). To investigate 13 
the functional role of TRPV1, PBEC cultures from bronchial brushings were cultured as 14 
described previously (20). These were obtained from mild asthmatic (n=4), non asthmatic 15 
patients with chronic cough (n=4) and healthy volunteers (n=4). 16 
Immunohistochemistry 17 
Twenty eight biopsies (10 healthy volunteer, 8 mild asthmatic and 10 severe asthmatic 18 
biopsies) were processed for immunohistochemistry (IHC) using local protocols as detailed 19 
in the online data repository. For TRPV1 and ER co-localisation experiments local protocols 20 
were employed as detailed in the online data repository. 21 
 22 
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Gene expression analysis 1 
Bronchial brushings and PBEC cultures 2 
Real-time PCR (qRT-PCR) analyses were performed using RNA from bronchial brushings using 3 
TaqMan® Gene Expression Assays (Applied Biosystems, Foster City, CA) as previously 4 
described (21). RNA was amplified (Ambion,) for Agilent (Santa Clara, CA) two color Whole 5 
Human Genome (WHG) 4x44k gene expression microarray analysis.   6 
 PBECs were trypsinised and total RNA extracted using the RNeasy Mini Kit (Qiagen, Hilden, 7 
Germany) and qRT-PCR performed using a 7300 Real Time PCR system (Applied Biosystems, 8 
Foster City, CA). More information including detail on GAPDH and TRPV1 forward and 9 
reverse primers is provided in the online data repository.  10 
Western Blotting 11 
Protein concentration was determined using BCA protein assay kit (Thermo Scientific, 12 
Wilmington, USA) and protein expression determined using a rabbit polyclonal TRPV1 13 
antibody (ab63083; Abcam, Cambridge, UK), at a dilution of 1:3000 followed by incubation 14 
for 1 h with the secondary antibody, HRP-labelled anti-rabbit (1:3000; Bio-Rad Laboratories, 15 
Hercules, CA, USA). More details provided in online data repository. 16 
TRPV1 agonists / antagonist experiments in PBECs 17 
Capsaicin is a selective TRPV1 agonist and in this study cultured PBECs were treated with either 10, 18 
25 or 50 µM capsaicin or control medium for 24 h and the concentration of IL-8 measured by ELISA 19 
(R & D Systems Europe Abingdon, UK). For the antagonist experiments, PBECs were pre-20 
treated for 20 min with 10 μM of the selective TRPV1 antagonist capsazepine. 21 
Patch clamp experiments 22 
11 
 
Whole-cell currents were recorded using borosilicate heat-polished patch pipettes (2-3 MΩ 1 
resistance when filled with the pipette solution) and an Axopatch 200B amplifier (Molecular 2 
Devices, Union City, CA, USA) interfaced to Digidata 1322A using the pClamp 9 software 3 
(Molecular Devices) as previously described by ourselves (22) and detailed in the online data 4 
repository.  5 
Data Analysis 6 
Data are presented as means ±SEM. For statistical analysis a one way ANOVA was performed 7 
with Bonferroni test for multiple comparisons. Kendall’s tau b statistical analysis was used to 8 
examine the trend in biopsy expression by participant group. Patch clamp data were 9 
analysed and plotted using Origin 8 (OriginLab, Northampton, MA, USA). A P value < 0.05 10 
was considered significant.  11 
 12 
RESULTS 13 
Confirmation of TRPV1 expression in cultured human bronchial epithelial cells.  14 
Gene expression for multiple members of the TRPV family including TRPV1 (but not TRPV5) 15 
was identified in PBECs from healthy controls (n=3) (Figure 1A). TRPV1 protein was detected 16 
at its expected molecular mass of 95 kDa by Western blotting in the same samples (Figure 17 
1B).   18 
Molecular identification and localisation (immunohistochemical expression) of TRPV1 in 19 
healthy and asthmatic epithelium 20 
Microarray 21 
12 
 
Using gene expression microarray analysis of bronchial brush samples from the Leicester 1 
cohort we found significantly greater levels of TRPV1 expression (median, IQR) in severe 2 
asthmatics (0.673, 0.452-0.761) compared to mild/moderate asthmatics (0.341, 0.167-0.538, 3 
p=0.008) and healthy volunteers (0.322, 0.155-0.410, p=0.004) (Figure 1C).  4 
Quantitative PCR.  5 
TRPV1 mRNA was detected in all of the epithelial brush samples. There was no difference in 6 
median (IQR) relative fold expression of TRPV1 mRNA calculated as Delta Delta CT values 7 
between groups: -1.262 (-3.598, 2.518), (, -2.523 (-4.040, 1.362) and -1.289 (-4.746, 1.624) in 8 
healthy volunteers, mild / moderate asthmatics and severe asthmatics respectively (see 9 
Figure E1 in online data repository) 10 
Immunohistochemistry  11 
Immunohistochemistry revealed bronchial epithelial expression of TRPV1 in healthy 12 
volunteers, mild/moderate asthmatics and severe asthmatics (Figures 2A, B and C, 13 
respectively). Dual labelling immunofluoresence confirmed the expression of TRPV1 on 14 
cytokeratin positive epithelial cells (Figures 3 A, B and C). We observed an intracytoplasmic 15 
distribution of the TRPV1 and to further characterise this we undertook additional 16 
experiments demonstrating immunohistochemistry staining of bronchial epithelial cells 17 
positive for TRPV1 (Figure 4A) and ER (Figure 4B) markers. Colocalisation was evident when 18 
the images were merged (Figure 4C).  19 
We observed There was greater TRPV1 expression in asthmatic epithelium compared to 20 
healthy subjects (Figure 45; p = 0.001).  21 
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Membrane current responses to TRPV1 agonist capsaicin 1 
Mean membrane capacitance of PBEC was 30.8±4.3 pF (n=6). In unstimulated cells, only 2 
small background currents could be recorded in the whole range of membrane potentials 3 
tested, from -100 to +140 mV (Figure 5A6A, left panel). The I-V relationship of the mean 4 
background current normalised by the membrane capacitance to account for some 5 
variations in cell size is shown in Figure 5B6B. It should be noted that composition of the 6 
external and pipette solutions was such that this facilitated isolation of cation currents but 7 
precluded activation of any potassium or calcium-dependent conductances. Capsaicin 8 
application (50 µM) caused rapid activation of large outwardly rectifying currents (Figure 9 
5A6A, middle panel), which is the characteristic “biophysical” signature of TRPV1 channels. 10 
This effect was completely reversible upon capsaicin wash-out (Figure 5A6A, right panel). 11 
Corresponding I-V relationships are shown in Figure 5C6C. The capsaicin-induced currents 12 
reversed close to 0 mV indicating their non-selective cation nature. 13 
To investigate the time course of these responses, voltage ramps over the same range of 14 
potentials were applied at 10 s interval. Figure 6A 7A shows a typical response to 50 µM 15 
capsaicin application consisting of rapid activation and desensitisation in the continuous 16 
presence of the agonist, which developed over 2-3 min. The I-V relationships which were 17 
measured in this experiment in control, at the peak response and after agonist wash-out are 18 
shown in Figure 6B 7B (compare to I-V curves in Fig. 6C measured by voltage steps), while 19 
the mean results are summarised in panel C. The increase in current amplitude in response 20 
to capsaicin was significant (p=0.007). 21 
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Reduction of external pH from 7.4 to 6.4 activated inward and outward currents in cells from 1 
healthy patients which were partially inhibited by the addition of the selective TRPV1 2 
antagonist capsazepine (5 µM; Fig. 8A). The mean capsazepine-sensitive I-V relation (Fig. 8B 3 
n=4) was similar in profile to the capsaicin-dependent currents exhibiting strong outward 4 
rectification and reversal close to 0 mV. 5 
 6 
Functional expression of TRPV1 in cultured human primary bronchial epithelial cells 7 
Dose–dependent induction of IL-8 release from cultured human PBECs by capsaicin  8 
Dose-dependent induction of IL-8 release by capsaicin was observed within each study 9 
group although there was no significant difference in fold increase in IL-8 between asthmatic 10 
and non asthmatic groups which may relate to sample size (data not shown). The dose 11 
dependent increase in IL-8 release when data from all three groups was therefore pooled 12 
has been presented in figure 7A9A. When compared to basal a marginal 1.25-fold increase in 13 
IL-8 release was observed following incubation with 10 μM capsaicin with significant 14 
increases of  1.76-fold (p<0.01) and 2.15 -fold (p<0.001) compared to basal observed 15 
following incubation with 25 and 50 μM doses of capsaicin, respectively.  16 
To further test the specificity of the capsaicin effect, we used selective TRPV1 blocker 17 
capsazepine. Capsazepine significantly inhibited capsaicin-induced IL-8 release compared to 18 
25 μM capsaicin alone (p<0.001) and compared to 50 μM capsaicin alone (p<0.001). The 19 
data for n=9 individual experiments is shown in Figure 7B9B. 20 
 21 
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 1 
DISCUSSION 2 
In this study we have shown for the first time that  TRPV1, which is primarily recognised as 3 
the major neuronal hot receptor (23, 24),  is expressed and functional in human bronchial 4 
epithelium. In primary bronchial epithelial cell cultures we have shown that pharmacological 5 
activation of the TRPV1 channel with capsaicin induces IL-8 release which can be attenuated 6 
by pre-treatment with the selective TRPV1 antagonist capsazepine.  7 
Interestingly, TRPV1 expression in the airway was increased in asthmatic subjects compared 8 
to healthy controls with a further increase in subjects with refractory asthma. Thus, over-9 
expression may have a role in symptoms associated with irritant exposure in asthma, 10 
particularly in patients with persisting symptoms despite treatment with high dose anti-11 
inflammatory therapy. Understanding the role of TRPV1 in refractory asthma may therefore 12 
identify a novel target for anti-inflammatory therapy in more severe disease. 13 
We believe that bronchial epithelial TRPV1 channels are ideally positioned to detect 14 
chemical and physical irritants (e.g. inflammatory mediators, environmental pollutants, acid 15 
pH and changes in temperature) in the airway lumen. To date, most of the focus has been 16 
on the role of neuronal TRPV1 in the human airway (14, 25). Direct activation of irritant 17 
neural receptors mediates reflex responses such as cough and bronchospasm, thus 18 
protecting the airway from noxious chemical and physical irritants. However, TRPV1 19 
expression at both an mRNA and protein level has been reported in a variety of non-20 
neuronal tissues and cell types and therefore we hypothesised that the airway responses to 21 
environmental stimuli might in part be regulated by the bronchial epithelial TRPV1 22 
16 
 
receptors. Recent studies in immmortalised human airways epithelial cell lines provide some 1 
support for this (17, 26) although evidence for this in human disease is lacking. In this 2 
studyHere we have providedprovide in vivo and ex vivo evidence of TRPV1 expression and 3 
function in human airway biopsies and cultured primary bronchial epithelial cells with 4 
specific relevance to refractory asthma. 5 
We observed an intracytoplasmic distribution of the receptor in bronchial epithelial cells 6 
which has been as observed in other cell types (27, 28). The intracellular localisation of 7 
TRPV1 (in particularOur finding of TRPV1 staining in the endoplasmic reticulum) in the 8 
airway epithelium is consistent with its functional role as a Ca2+ store release channel 9 
regulating intracellular Ca2+ homeostasis. Robust membrane current responses to the TRPV1 10 
agonist capsaicin (Figs. 5 and 6) suggest strongly that plasmalemmal TRPV1 is also expressed 11 
and functional in PBEC, although the precise location and function of bronchial epithelial cell 12 
membrane and intracellular TRPV1 requires further study. We also observed TRPV1 staining 13 
on a number of submucosal cells although the focus of this present study is confined to the 14 
bronchial epithelial expression. Previous studies from chronic coughers (14) and healthy 15 
subjects (15) have reported only sparse TRPV1 expression in the airway epithelium, although 16 
greater expression has been reported in the human upper airway (29). We suggest 17 
dDifferences in tissue processing, antibodies used and clinical phenotype may explain the 18 
discrepancy. To overcome issues regarding specificity of antibodies weIn our studies to 19 
evaluated the functional properties of TRPV1 on bronchial epithelium. In these experiments 20 
we saw that TRPV1 on PBECs responded to the TRPV1 agonist capsaicin with the release of 21 
pro-inflammatory mediators and that thiswhich was blocked by capsazepine, a TRPV1 22 
selective antagonist. We chose to measure Ccapsaicin induced  IL-8 release from bronchial 23 
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epithelial cells  as this hadhas been previously observed in  both human esophageal (30) and 1 
human corneal epithelial cells (31) but not before in culturedprimary bronchial epithelial 2 
culturesPBECs. In addition,As IL-8 is known to induce and maintain neural sensitization and 3 
activation of nociceptors (32, 33). Therefore, our data provide a mechanistic link whereby 4 
activation of activation of bronchial epithelial TRPV1 receptors by environmental irritants or 5 
changes in airway pH or temperature (during exacerbations) may sensitize airway sensory 6 
neurones and contribute to the airway and cough hypersensitivity that characterises asthma 7 
through the cross-talk between epithelial and neuronal TRPV1.  8 
Studies in immortalised respiratory cell lines suggest Aairway epithelial TRPV1 has been 9 
shown to regulates cell apoptosis in response to environmental irritants such as particulate 10 
matter and ash (34).  These have been confined to immortalised respiratory cell lines 11 
whereas our findingsHere, we provide the first evidence of a functional airway epithelial 12 
TRPV1 channel function in primary cells from the airway. We also provide further evidence 13 
of TRPV1 channel function Iin our the whole-cell patch clamp experiments on PBECs our. 14 
These results provided a direct evidence of for the presence of functional TRPV1 in the 15 
plasma membrane that can thus mediate membrane depolarisation and calcium influx; 16 
steps which are necessary for release of pro-inflammatory mediators (35). Both kinetics and 17 
voltage-dependent properties of capsaicin-induced currents in PBEC are consistent with 18 
TRPV1 biophysical features, such as slow activation/deactivation and strong outward 19 
rectification.  20 
Asthmatics commonly report symptoms triggered by a variety of chemical and physical 21 
irritants and because TRP channels have the capacity to sense a vast range of stimuli, and 22 
their role in airways disease is currently under intense investigation (1). In our 23 
18 
 
immunohistochemical studies we have shown that TRPV1 is over expressed in the bronchial 1 
epithelium of asthmatics compared to healthy subjects and patients with refractory asthma 2 
express more epithelial TRPV1 than those with mild/moderate asthma. This was supported 3 
by our microarray analysis demonstrating confirming increased expression of TRPV1 genes 4 
in the more severe asthmatics. Although on quantitative PCR, mRNA was not concordant 5 
with protein abundance, it has become increasingly clear that at the genomic level, mRNA 6 
expression does not consistently predict corresponding protein levels (36, 37). This may 7 
because of complex post-transcriptional and translational modification and /or that different 8 
biological mRNA and protein degradation rates may affect correlation. Post translational 9 
modification of TRPV1 has been described in experimentally induced tissue injury (38) and 10 
therefore may occur in the inflamed asthmatic airway.  11 
While the vast majority of asthmatics respond to standard doses of current treatments (in 12 
particular corticosteroids), a proportion remain symptomatic despite treatment at GINA 13 
Step 4/5 and are considered to have difficult or treatment refractory asthma. Our finding 14 
that bronchial epithelial TRPV1 is over expressed in human bronchial epithelium and 15 
upregulated in refractory (steroid-resistant) asthma suggests that it its activation may 16 
represent a novel pro-inflammatory pathway. Clinical trials of TRP receptor antagonists in 17 
man have been undertaken in other abnormal hypersensitive states including neuropathic 18 
pain and these drugs may prove effective in improving symptom control in asthma as well.  19 
Our findings suggest that the bronchial epithelium may sense and respond to environmental 20 
stimuli via TRPV1 activation. However it is not clear how bronchial epithelial cells signal to 21 
afferent sensory nerves. We suggest that release of sensitizing mediators such as IL-8 may 22 
be one such mechanism. Such mediators may enhance and augment neurogenic 23 
19 
 
inflammation and nociceptive signalling. Therefore, pharmacological modulation of this 1 
receptor may be useful in the treatment of uncontrolled asthma. 2 
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Table 1. Demographic characteristics of the Asthmatic Participants and Healthy Volunteers (Belfast 1 
and Leicester cohorts combined). Comparison with the Healthy Volunteer group †p<0.001, §p<0.001, 2 
llp<0.001, ** p<0.001, §§p<0.001, ‡ ‡ p<0.05, llllp<0.001. Comparison with Mild to Moderate 3 
Asthmatics: †p<0.001, ‡p=0.007, §p<0.001, ll p<0.001, ** p<0.001, †† p<0.0001, §§p<0.05, ***p<0.001. 4 
 Healthy 
Volunteers 
(n=22) 
Mild to Moderate 
Asthmatics 
(n=30) 
Severe Asthmatics 
(n=31) 
p Value 
Age (y), median (IQR)  30 (22 - 45) 29 (24 - 39) 48 (38 - 54)† <0.0001 
Sex, M/F 10/12 14/16 22/9 0.09 
Duration of asthma (y), 
mean  SD  
N/A 12 ±10 22±15‡ 0.007 
Atopy, (n) 11 21 23 0.16 
FEV1 (L/min), mean  SD  3.67±0.78 3.32±0.77 2.48±0.67
§ <0.0001 
FEV1 (%predicted), mean 
 SD  
102.8 11.9 93.516.0 75.9 16.9 ll  <0.0001 
FEV1/ FVC, mean  SD 82.1 9.8 75.9 10.6 64.6 11.1**
  <0.0001 
Inhaled steroid (n) 
BDP equivalent (µg), 
median (IQR) 
 
Maintenance systemic 
steroids (n) b  
 
 
0 
0 
 
 
0 
19 
400 (0 - 800) 
 
 
0 
31 
1600 (1200 - 1600)††  
 
 
15 (median dose 
prednisolone 5 mg 
[0 – 10 mg] plus 1 
subject maintenance 
intramuscular 
triamcinolone) 
 
<0.0001 
Theophylline, (n) 0 1 17 <0.0001 
Long-acting 2-agonists, 
(n) 
0 14 31 <0.0001 
Prior smoking 1 5 13 0.004 
25 
 
history (n) 
[pack years, median 
range] 
 
[4]  
 
[1, 1-10] 
 
[2.5, 1 – 20] 
Eosinophils (109/L), 
median (IQR) 
0.1 (0.07 - 0.21) 0.26 (0.14 - 0.45)‡‡  0.49 (0.25 - 0.74)§§  <0.0001 
IgE (kU/L), geometric 
mean (95% confidence 
interval) 
24.6 (13.3 - 45.8) 159.8 (89.8 - 
284.6)llll 
238.5 (136.2 - 
417.5)*** 
<0.0001 
 Calculated by ANOVA with Bonferroni’s Multiple Comparisons Test (parametric) or Kruskal-Wallis 1 
with Dunn’s Multiple Comparison Test (non-parametric) or t-test when only asthma groups 2 
compared or Chi-squared for categorical variables (sex, atopy, theophylline, long-acting 2-agonists, 3 
smoking history). 4 
 5 
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Table 2. Demographic characteristics of the cough variant asthmaticmild asthmatic, non-asthmatic 1 
cough and healthy volunteers recruited for experiments on cultured primary bronchial epithelial 2 
cells.  3 
 Healthy volunteers  
(n=4) 
Cough variantmild 
asthmatics 
 (n=4) 
Non asthmatic 
coughers  
(n=4) 
P value 
Age, (y) 
Median (IQR) 
35.5 (21.3-43.8) 46.0 (39.3-56.8) 58.0(45.0-72.5) 0.05 
Sex, M/F 1/3 0/4 0/4 0.336 
Duration of cough 
(m) Mean ±SD 
N/A 49.5 (30.0) 57.5 (27.0) 0.950 
FEV1 (L/min) 
Mean ±SD 
3.45 (0.65) 2.52 (0.29) 2.3 (0.34)* 0.014 
FEV1, % pred 
Mean ±SD 
107.3 (10.59) 105.6 (15.23) 118.0 (21.28) 0.530 
FEV1/ FVC 
Mean ±SD 
86.6 (10.6) 82.73 (4.11) 80.2 (3.2) 0.446 
Atopy (n) 0 0 0 N/A 
Inhaled steroid (n) 0 4 0 N/A 
Prior smoking (n) 0 0 0 N/A 
Calculated by ANOVA with Bonferroni’s Multiple Comparisons Test (parametric) or Kruskal-Wallis 4 
with Dunn’s Multiple Comparison Test (non-parametric) or t-test when only cough groups compared 5 
or Chi-squared for categorical variables (gender). 6 
 7 
 8 
 9 
 10 
 11 
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 1 
Legends to Figures 2 
Figure 1: A. Molecular expression of TRPV channels subtypes in human primary bronchial 3 
epithelial cells. Conventional RT-PCR showing the expression of TRPV family subtypes 4 
including TRPV1 in PBECs from healthy controls (n=3) B. Expression of TRPV1 protein in 5 
primary bronchial epithelial cells (PBECs). Protein was extracted and analysed by Western 6 
blotting (30 μg protein per sample). Blots were probed using a TRPV1 specific primary 7 
antibody (Abcam 63083). TRPV1 specific bands were observed at the molecular weight of 95 8 
KDa in PBECs (lanes 2 to 4, upper panel). TRPV1 transfected HEK cells were used as a positive 9 
control (lane 1, upper panel). β-Tubulin (lower panel) was used to ascertain equal loading 10 
(Abcam 6046). Results are representative of two independent experiments. C. Gene 11 
expression microarray analysis of bronchial brush samples from healthy, mild/moderate 12 
and severe asthmatics. Gene expression microarray analysis was performed on fresh 13 
bronchial brush samples from the Leicester cohort comprising severe asthmatics (n=12), 14 
mild/moderate asthmatics (n=16) and healthy subjects (n=8). TRPV1 was significantly 15 
elevated in severe asthma versus mild moderate asthma (* p=0.008) and healthy volunteers 16 
(** p=0.004).  17 
 18 
Figure 2 - Digital photographic images (A-D) of TRPV1 expression in JB4 sections from  (A)  19 
healthy control: showing only patchy or focal areas of low intensity epithelial expression;  (B) 20 
moderate asthmatic: where the majority of epithelial and submucosal cells  express antigen; 21 
(C) severe asthmatic: where there is  widespread and strong epithelial and submucosal cell 22 
28 
 
expression of TRPV1. Sections incubated in the absence of antibodies showed no staining; a 1 
representative image is shown in (D). Representative immunohistochemistry shown at X 400 2 
magnification 3 
 4 
 Figure 3 – Confocal microscopy images (A-C) of double staining immunocytochemistry 5 
demonstrating localisation of TRPV1 channels in bronchial epithelium (healthy subject). 6 
Bronchial epithelial cells identified by positive red staining with the cytokeratin antibody 7 
AE1AE3 (A) were also positive for the TRPV1 (green) (B) and co-localisation was evident 8 
when the images were merged (yellow) (C).  Representative immunohistochemistry shown 9 
at X 400 magnification 10 
 11 
Figure 4: TRPV1 and ER colocalisation in human bronchial epithelial cells. Representative 12 
confocal microscopy images at X 40 magnification (A-C) showing immunohistochemistry 13 
staining of bronchial epithelial cells positive for TRPV1 (A) and ER (B) markers. Colocalisation 14 
was evident when the images were merged (C; orange/yellow). DAPI stained blue nuclei (C). 15 
Scale bar = 100 μm.  16 
 17 
 18 
Figure 4 5 Quantitative immunohistochemical epithelial expression for TRPV1 in bronchial 19 
biopsies. TRPV1 expression is increased in the bronchial epithelium of severe asthmatic 20 
patients. There was a trend to increased TRPV1 expression with severity of asthma (p=0.001, 21 
Kendall’s tau-B statistic).  22 
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Figure 56. Whole-cell PBEC (healthy subject) membrane current responses to capsaicin 1 
application (50 µM) measured by voltage-steps. A. Superimposed current traces evoked by 1 2 
s voltage steps before, in the presence of, and after capsaicin wash-out, as indicated. The 3 
dotted Dotted line indicates zero-level current. B. Mean normalised I-V relationship of 4 
background current (n=4). C. I-V relationships for the current amplitude measured at the 5 
end of each voltage step in the experiment illustrated in panel A. 6 
Figure 67. Time course of the capsaicin membrane current response. A. Current 7 
amplitude was monitored by applying voltage ramps from -100 to 140 mV at 10 s interval. 8 
Circles show current amplitude at 140 mV. B. The I-V relationships were derived from the 9 
ramps applied before, at the peak response and 3 min after wash-out of the drug as 10 
indicated. C. Mean normalised I-V relationships measured before (squares) and after 11 
(circles) capsaicin application (n=3). In each cell, current amplitude at 140 mV in control was 12 
normalised as 1.0. 13 
Figure 8. Whole-cell PBEC (healthy subject) membrane current responses to reduced 14 
external pH measured by voltage ramps. A. Superimposed current traces evoked by voltage 15 
ramps from -100 to 140 mV at 10 s interval in pH 7.4 and pH 6.4 (± capsazepine; 5µM) 16 
external solutions as indicated. The dotted line indicates zero-level current. B. Mean ± SEM  17 
I-V relationship (normalized for cell capacitance) of capsazepine-sensitive current (n=4). 18 
Figure 79. Capsaicin induces IL-8 release from human PBECs (asthmatic and non-asthmatic 19 
subjects). PBECs were treated ( for24 hours) with 10, 25 or 50 μM capsaicin or control 20 
medium. Supernatants were collected after 24 h and ELISA was performed to measure the 21 
release of IL-8. Values are expressed as the mean release over basal ± SEM. A. Capsaicin-22 
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induced IL-8 release ***p<0.001 compared to control;, measured using a Kruskal-Wallis test 1 
with Dunn’s multiple comparison test for (n=12 individual experiments). B. Capsazepine 2 
inhibits capsaicin induced IL-8 release from human PBECs. PBECs were pre-treated for 20 3 
min with 10 μM capsazepine. Following which media was replacedthen with 10, 25 or 50 μM 4 
capsaicin or control medium with or without capsazepine. Supernatants were collected after 5 
24 h and ELISA was performed to measure the release of IL-8. Values are expressed as the 6 
mean release over basal ± SEM. Capsazepine significantly inhibited capsaicin-induced IL-8 7 
release *p<0.001 compared to 25 μM (*p<0.001) and capsaicin alone and 50 μM 8 
(**p<0.001) compared to 50 μM capsaicin alone;, measured using one way ANOVA with 9 
Bonferroni’s multiple comparison test for (n=9 individual experiments). 10 
 11 
 12 
 13 
 14 
 15 
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Study Subjects  
The studies were approved by the Research Ethics Committee of both Institutions (Belfast - 
Office of Research and Ethics Committee of Northern Ireland reference 06/NIR02/114 and 
09/NIR02/51, Leicester - Leicestershire, Northamptonshire, & Rutland Research Ethics Committee 
reference 04/Q2502/74). Written informed consent was gained from all participants prior to 
their involvement.  
Bronchial biopsies:  
Belfast Cohort: Participants with refractory asthma were recruited from the Belfast City 
Hospital where systematic evaluation protocols ensure patients have well-characterised 
refractory asthma. All participants had persisting symptoms despite treatment at Step 4 or 5 
of the GINA guidelines Global Initiative for Asthma (GINA) (E1). Mild to moderate asthmatic 
and normal participants were recruited by advertisement and had a clinical diagnosis of 
asthma with a current history of recurrent wheezing and response to asthma medication. 
Healthy volunteers had no history of asthma or persistent respiratory symptoms and normal 
lung function. All asthmatic participants were clinically stable on their usual medication at 
the time of bronchoscopy, and all participants had an FEV1 of greater than 60% predicted. 
Demographic details are shown in Table 1 of the main paper. 
Leicester cohort: For the gene expression studies, asthmatic subjects (n=36) and healthy 
volunteers (n=12) were recruited from respiratory clinics including the Leicester Difficult 
Asthma Clinic, from staff at Glenfield Hospital, and from the general population through 
advertisement (Leicester cohort). Subjects with asthma gave a suggestive history and had 
objective evidence of variable airflow obstruction as indicated by one or more of the 
following: (1) methacholine airway hyperresponsiveness (PC20 FEV1 < 8 mg/mL), (2) >15% 
improvement in FEV1 10 minutes after 200 g inhaled salbutamol, (3) peak expiratory flow 
(>20% maximum within-day amplitude from twice-daily peak expiratory flow measurements 
over a period of 14 days). Subjects underwent spirometry; allergen skin prick tests for 
Dermatophagoides pteronyssinus, dog, cat, grass pollen and Aspergillus fumigatus; a 
methacholine inhalation test using the tidal breathing method; and sputum induction using 
incremental concentrations of nebulized hypertonic saline (i.e., 3%, 4%, and 5%, each for 5 
min)(E2). Subjects with asthma also kept a diary card for 2 weeks prior to bronchoscopy, 
recording daytime and night-time symptoms, daily short-acting 2-agonist use and twice 
daily peak expiratory flow (PEF). Asthma severity was defined by British Guideline on the 
Management of Asthma treatment steps (mild = step 1, 2-agonist only; moderate = steps 2 
and 3, inhaled corticosteroid ≤800 mg beclomethasone equivalent per day ± long-acting 2-
agonist; severe = step 4 and 5) (E3). Of the 16 severe patients at step 4/5, 13 met the 
American Thoracic Society criteria for refractory asthma (E4). 
In both cohorts, all participants were current non-smokers with no upper or lower 
respiratory tract infection in the 6 weeks prior to their bronchoscopy. All asthmatic 
participants were clinically stable on their usual medication at the time of bronchoscopy. 
Demographic details for each cohort are shown in Table 1 in the main manuscript.  
 
 
Primary bronchial epithelial cell (PBEC) cultures: To investigate the functional role of TRPV1 
we performed a series of experiments on primary bronchial epithelial cell (PBEC) cultures 
from bronchial brushings obtained from mild asthmatic (n=4) and non asthmatic patients 
with chronic cough (n=4) referred to the Belfast City Hospital specialist cough clinic (E5). 
Healthy volunteers (n=4) were recruited by local advertisement. Demographic details for 
this cohort are shown in Table 2 in the main manuscript. 
Bronchoscopy and samples 
Bronchoscopy was performed using a standard technique. In brief, after intravenous 
sedation and local anaesthesia with topical lignocaine, bronchial biopsies and bronchial 
brushings were obtained from lobar / segmental airways. One biopsy from each participant 
was immediately placed in RNA preservative (RNAlater, Ambion, Austin, TX) and submitted 
for microarray analysis and qPCR and 3 biopsies placed immediately into dry acetone 
containing protease inhibitors (iodoacetamide and PMSF) and fixed overnight at -20C. 
Brushings were placed in RNAlater or Promocell™ medium containing 
penicillin/streptomycin and Primocin™ for cell culture (Promocell UK). PBECs were cultured 
using methods developed in our laboratory which resulted in homogenous cultures of basal 
epithelial cells (E6). 
For immunohistochemistry (IHC), biopsy samples were processed using local protocols. 
Twenty eight biopsies (10 healthy volunteer, 8 mild asthmatic and 10 severe asthmatic 
biopsies) were available for immunohistochemistry. Infiltration and embedding with JB4 
resin was performed as previously described (E7). Two m sections were cut from each 
biopsy. Endogenous peroxidise was blocked with 0.3% hydrogen peroxide. All sections were 
pressure cooked in 0.01M Tris-EDTA pH9.0 on full steam for 3 minutes for antigen retrieval. 
Sections were incubated with TRPV1 polyclonal antibody (1:200, Abcam), overnight at 4°C, 
then primary antibodies were detected by incubation for 30 min at RT in peroxidase-labelled 
EnVision anti-rabbit secondary antibody (Dako, Ely, UK) using 3,3’-diaminobenzidine (DAB; 
Dako, Ely, UK) as chromagen.   On selected tissue sections from this series, 
immunofluorescence was carried out to permit high resolution analysis of TRPV1 antigen 
distribution.  Sections were treated as for IHC and following incubation in a mix of TRPV1 
and a monoclonal antibody to the epithelial specific antibody AE1AE3 (1:50, Dako). Antigen 
binding sites were detected with a mixture of anti-mouse Alexa 568 and anti-rabbit Alexa 
488 (Invitrogen). Sections were counterstained with DAPI hardset mounting medium 
(Vector). All fluorescently stained slides were assessed and digital fluorescent images 
acquired with a Leica DFC350 FX digital camera and processed using Leica FW4000 software. 
Immunostained sections were evaluated by two independent persons, following which 
results were discussed and consensus scoring applied to any conflicting results. A 4-point 
scoring system was used: 0 - no detectable expression in epithelium or submucosa; 
1 - patchy or focal areas of low intensity epithelial expression, not all cells expressing 
positivity for protein, scattered positivity in submucosa; 2 - moderate / majority of epithelial 
and submucosal cell expression; 3 - widespread and strong epithelial and submucosal cell 
expression.  
TRPV1 and ER colocalisation in human bronchial epithelial cells.  
Human bronchial epithelial cells were grown on coverslips and fixed in 4% 
paraformaldehyde (PFA) for 30 minutes at RT. Cells were briefly washed in Phosphate 
Buffered Saline (PBS) before being permeabilised with 0.1% Triton X-100 in PBS for 20 
minutes at RT. Cells were blocked with 10% Bovine Serum Albumin (BSA) in PBS for 1 hour at 
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RT and incubated with primary antibodies, mouse monoclonal anti-KDEL (1:500), ER marker 
and rabbit polyclonal anti-VR1 (1:200), TRPV1 marker (AB12223 and Ab63083 respectively; 
Abcam, Cambridge, UK) overnight at 40C, followed by incubation for 1 hour at RT with 
secondary antibodies, Alexa Fluor goat anti-mouse 488 (1:500; Invitrogen) and Alexa Fluor 
goat anti-rabbit 568 (1:500; Invitrogen). Cell nuclei were stained using Vectashield mounting 
medium containing DAPI (Vector Labs, Peterborough, UK). Staining was visualised and 
images captured using Nikon EZ-C1 confocal system running C1 acquisition software (Nikon 
UK Ltd. Surrey, UK) at x40 magnification. 
 
Gene expression analyses 
RNA was isolated from homogenized bronchial biopsies and real-time PCR (qPCR) was 
performed as described previously  (E8).  TaqMan® Gene Expression Assays (Applied 
Biosystems, Foster City, CA) were purchased and conducted per manufacturer’s instructions 
for TRPV1. RNA was amplified (Ambion,) for Agilent (Santa Clara, CA) two color Whole 
Human Genome (WHG) 4x44k gene expression microarray analysis.  Universal Human 
Reference RNA (Stratagene, La Jolla, CA) was used for the reference channel.  Probe 
intensities were transformed as log2 ratios of test and reference channels calculated by the 
Agilent Feature Extraction software, protocol GE2-v5_95 (Agilent).  Flagged outliers were 
not included in any subsequent analyses. All gene expression analyses and plotting were 
performed using the R Project software package, version 2.10.1 (refer to http://www.R-
project.org). 
 
Quantitative Real-Time PCR  
Bronchial brushings 
Real-time PCR (qRT-PCR) analyses were performed using RNA from homogenized bronchial 
brushings (36 subjects; 10 HV, 16 MA  and 15 SA) using TaqMan® Gene Expression Assays 
(Applied Biosystems, Foster City, CA) as previously described. The delta-delta Ct method was 
used to calculate relative fold expression with GAPDH as housekeeping gene  
PBEC cultures 
 PBECs were trypsinised and cells lysed using Qiagen RLT buffer (Qiagen, Hilden, Germany) 
before homogenisation using QIAshredders (Qiagen, Hilden, Germany). RNA was then 
extracted using the RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA concentration was 
measured with the nanodrop spectrophotometer (Thermo Scientific, Wilmington, USA) and 
1μg RNA was used to synthesise cDNA using the high capacity cDNA reverse transcription kit 
(Applied Biosystems, Foster City, CA). PBEC cDNA was mixed with Power Sybr Green PCR 
master mix (Applied Biosystems, Foster City, CA) and either GAPDH or TRPV1 forward and 
reverse primers (Table E1). The following PCRs were performed in a 7300 Real Time PCR 
system (Applied Biosystems, Foster City, CA). Melting curves showed formation of only one 
gene product per primer pair. Normalisations and calibrations of the data from all studies 
were performed with the 2-ΔΔCT method as described in Applied Biosystems User Bulletin No. 
2 (P/N 4303859) (27). Delta CT was calculated as target gene expression (CT) minus internal 
housekeeping control, GAPDH gene expression (CT). Human Universal Reference RNA 
(Clontech, P/N 639654) was prepared as cDNA and utilised as plate calibrators. DeltaDelta 
CT was calculated as sample Delta CT minus plate calibrator Delta CT. GAPDH and TRPV1 
forward and reverse primers are detailed in table E1 below.  
Table E1. Forward and reverse primers for TRPV1 and GAPDH 
Primer name Forward Reverse Size (bp) 
TRPV1 GCCTGGAGCTGTTCAAGTTC GCCTGAAACTCTGCTTGACC 452 
TRPV2 CCAGCTCTCCAGTTTTCAGG GTTCAGCACAGCCTTCATCA 365 
TRPV3 TTCCTCATGCACAAGCTGAC TGCGCTTCACAAAGTCATTC 490 
TRPV4 CCCGTGAGAACACCAAGTTT GAAGAGCGTAATGACCTCGC 374 
TRPV5 TTGCTCAGTTGCTGTCATCC GCTCCTCTTTGTCGAACGTC 307 
TRPV6 TCACTTCGCTTCCTGGAACT ACACGCTTTCCACAAGCTCT 401 
GAPDH GCTCTCTGCTCCTCCTGTTC AAATCCGTTGACTCCGACC 100 
 
Source:  Invitrogen 
 
 
Western Blotting 
PBECs were collected and snap frozen, homogenised and lysed in RIPA buffer supplemented 
with protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). Protein 
concentration was determined using BCA protein assay kit (Thermo Scientific, Wilmington, 
USA). 30μg of total protein was separated on the 8% SDS-Polyacrylamide gel by 
electrophoresis and transferred to Hybond-P PVDF membrane (GE Healthcare Life Sciences, 
Buckinghamshire, UK). The membrane was blocked for 30 min in 3% BSA/ PBS and then 
probed overnight in 3% BSA/PBS with a rabbit polyclonal TRPV1 antibody (ab63083; Abcam, 
Cambridge, UK), at a dilution of 1:3000. Followed by incubation for 1 h with the secondary 
antibody, HRP-labelled anti-rabbit (1:3000; Bio-Rad Laboratories, Hercules, CA, USA). Images 
were obtained using UVP bioimager (UVP, Cambridge, UK). Benchmark Pre-stained protein 
standards (Invitrogen, Paisley, UK) were used to determine molecular mass. 
 
Patch clamp experiments 
Whole-cell currents were recorded using borosilicate heat-polished patch pipettes (2-3 MΩ 
resistance when filled with the pipette solution) and an Axopatch 200B amplifier (Molecular 
Devices, Union City, CA, USA) interfaced to Digidata 1322A using the pClamp 9 software 
(Molecular Devices). Series resistance was compensated by about 70%. Holding potential 
was -40 mV. Steady-state current-voltage (I-V) relationships were measured by applying 
either voltage steps (test potentials from -100 to +140 mV with a 20 mV increment) or slow 
voltage ramps from -100 to +140 mV. To monitor the time course of TRPV1 activation by 
capsaicin, the voltage ramps were applied at 10 s interval. The I-V curves obtained by the 
voltage ramp and step protocols were similar confirming steady-state channel activity at 
each test potential when ramps were used. 
For experiments involving the addition of capsaicin the The external solution contained 
(mM): NaCl 120, glucose 12, HEPES 10, pH 7.4 (adjusted with NaOH). Pipette solution 
contained (mM): CsCl 80, MgATP 1, creatine 5, GTP 1, D-glucose 5, HEPES 10, BAPTA 10, 
CaCl2 4.6 ([Ca
2+]i=100 nM), pH 7.4 (adjusted with CsOH). For experiments involving altered 
pH the external solution contained (mM): NaCl 150, CsCl 6, MgCl2 1.3, CaCl2 2, Glucose, 5; 
HEPES, 10; pH7.4 or 6.4 with Tris. Pipette solution contained (mM): CsOH 130, D Gluconic 
Acid 120, MgCl2 1, EGTA 0.5 ([Ca
2+]i= 30 nM), pH 7.2 with Tris. 
IL-8 ELISA 
IL-8 concentrations were measured from aliquots of culture medium taken 24 h following 
treatment with capsaicin (Enzo Life Sciences, Exeter, UK) using a commercial ELISA kit from 
R & D Systems Europe (Abingdon, UK). 
Data Analysis 
Data are presented as means ±SEM. For statistical analysis a one way ANOVA was 
performed with Bonferroni test for multiple comparisons. Kendall’s tau b statistical analysis 
was used to examine the trend in biopsy expression by participant group. Patch clamp data 
were analysed and plotted using Origin 8 (OriginLab, Northampton, MA, USA). A P value < 
0.05 was considered significant.  
RESULTS 
Real time PCR (qRT PCR) analysis of fresh bronchial brush samples from the Leicester 
cohort comprising healthy, mild/moderate and severe asthmatics. Analysis was performed 
on fresh bronchial brush samples from the Leicester cohort comprising severe asthmatics 
(n=15), mild/moderate asthmatics (n=16) and healthy subjects (n=10). TRPV1 mRNA was 
detected in all of the epithelial brush samples. There was no difference in median (IQR) 
relative fold expression of TRPV1 mRNA calculated as Delta Delta CT values between groups: 
-1.262 (-3.598, 2.518), (, -2.523 (-4.040, 1.362) and -1.289 (-4.746, 1.624) in healthy 
volunteers, mild / moderate asthmatics and severe asthmatics respectively (see figure E1 
below). 
 
 
Online Figure Legend  
Figure E1: Real time PCR (qRT PCR) expression of TRPV1 in fresh bronchial epithelial brush 
samples from healthy volunteers, mild/moderate asthmatics and severe asthmatics. 
Analysis of fresh bronchial brush samples from the Leicester cohort comprising healthy 
(n=10), mild/moderate (n=16) and severe asthmatics (n=15). Data presented as median 
(IQR) relative fold expression of TRPV1 mRNA calculated as delta delta CT values.  
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ABSTRACT (250 words) 4 
Background: The airway epithelium is exposed to a range of physical and chemical irritants 5 
in the environment which are known to trigger asthma. Transient Receptor Potential (TRP) 6 
cation channels play a central role in sensory responses to noxious physical and chemical 7 
stimuli. Recent genetic evidence suggests an involvement of TRPV1, one member of the 8 
vanilloid subfamily of TRP channels, in the pathophysiology of asthma. The functional 9 
expression of TRPV1 on airway epithelium has yet to be elucidated.    10 
Objective: In this study we examined the molecular, functional and immunohistochemical 11 
expression of TRPV1 in the asthmatic and healthy airway.  12 
Methods: Bronchial biopsies and bronchial brushings were obtained from healthy 13 
volunteers (n=18), mild to moderate asthmatics (n=24) and refractory asthmatics (n=22). To 14 
investigate the functional role of TRPV1, cultured primary bronchial epithelial cells (PBEC) 15 
from mild asthmatics (n=4), non asthmatic coughers (n=4) and healthy subjects (n=4) were 16 
studied. 17 
Results: Quantitative immunohistochemistry revealed significantly more TRPV1 expression 18 
in asthmatics compared to healthy subjects and with greatest expression in the refractory 19 
asthmatics (p=0.001). PCR and Western blotting analysis confirmed gene and protein 20 
expression of TRPV1 in cultured primary bronchial epithelial cells (PBEC). Patch-clamp 21 
electrophysiology directly confirmed functional TRPV1 expression in all three groups. In 22 
5 
 
functional assays, the TRPV1 agonist capsaicin induced dose dependent interleukin-8 (IL-8) 1 
release which could be blocked by the antagonist capsazepine. Reduction of external pH 2 
from 7.4 to 6.4 activated a capsazepine-sensitive outwardly-recifiying membrane current. 3 
 4 
Conclusions: Functional TRPV1 channels are present in the human airway epithelium and 5 
are over-expressed in the airways of refractory asthmatics. These channels may represent a 6 
novel therapeutic target for uncontrolled asthma.  7 
8 
6 
 
Clinical Implications (30 words) 1 
TRPV1 is a functional channel activated by physical and chemical irritants. We report its 2 
overexpression in asthmatic airway epithelium most notably in severe disease suggesting a 3 
role in uncontrolled asthma. 4 
Capsule summary (35 words) 5 
The Transient Receptor Potential vanilloid-1 (TRPV1) channel regulates responses to irritant 6 
stimuli. We report TRPV1 overexpression in asthmatic airway epithelium most notably in 7 
severe disease suggesting its potential as a therapeutic target for uncontrolled asthma. 8 
 9 
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INTRODUCTION 1 
During an exacerbation of asthma, the airways become hypersensitive and patients are 2 
often troubled with bouts of cough and wheeze following exposure to relatively innocuous 3 
stimuli such as aerosols, strong odours or changes in air temperature. The precise 4 
mechanism for this airway hypersensitivity is not known but upregulation of receptors 5 
responsible for sensing chemical and physical stimuli may be relevant. The recently 6 
described Transient Receptor Potential (TRP) proteins, a family of Ca2+ permeable non 7 
selective cation channels which sense a vast array of chemical and physical stimuli (1, 2), are 8 
believed to have an important role in the regulation of airway function in both health and 9 
disease (3, 4). Recent data has provided genetic evidence for the involvement of one 10 
subfamily member, TRP vanilloid 1 (TRPV1) in asthma pathophysiology (5).  11 
TRPV1 is activated by capsaicin (the pungent principle contained in hot chilli peppers) and 12 
inhaled capsaicin causes cough (6) and bronchospasm (7) in asthmatics. The airway 13 
inflammatory events which accompany an exacerbation of asthma include a rise in airway 14 
temperature (8), acidosis (9) and release of mediators derived from lipoxygenase 15 
metabolism of arachidonic acid (4, 10). TRPV1 is primarily recognised as a heat thermal 16 
sensor, but it is also readily activated by low extracellular pH (11, 12) and lipoxygenase 17 
products such as leukotriene B4. (13). TRPV1 receptors are expressed in several cell types in 18 
human airway including sensory neurones (14), smooth muscle cells (15) and epithelial cells 19 
from both the upper (16) and lower airway (17). As the bronchial epithelium has an 20 
important role in sensing and responding to noxious stimuli we hypothesised that TRPV1 is 21 
over expressed in the airway epithelium of asthmatics, in particular those with difficult-to-22 
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treat asthma. Further we considered that the inflammatory response following irritant 1 
activation of airway epithelial TRPV1 may contribute to heighted neuronal reflexes 2 
responsible for cough and bronchospasm in asthma.may .  3 
In this study, we examined both TRPV1 expression and function in human bronchial 4 
epithelium. In addition we provide evidence for the overexpression of TRPV1 in the airways 5 
of severe asthmatics compared to mild asthmatics and healthy subjects. Some of the results 6 
of these studies have been reported in abstract form (18). 7 
 8 
METHODS AND MATERIALS 9 
Full methodological details are provided in an online data repository 10 
Study Subjects 11 
Participants with refractory asthma were recruited from the Belfast City Hospital. All had 12 
persisting symptoms despite treatment at Step 4 or 5 of the Global Initiative for Asthma 13 
(GINA) guidelines. Mild to moderate asthmatics had a clinical diagnosis of asthma with a 14 
current history of recurrent wheezing and documented response to asthma medication. 15 
Bronchial biopsy samples from this Belfast cohort were analysed using 16 
immunohistochemistry (IHC).  For examination of in vivo gene expression of TRPV1 in airway 17 
epithelium an additional cohort of subjects from Leicester were recruited. Demographic 18 
details of both cohorts are shown in Table 1. To investigate the functional role of TRPV1, 19 
primary bronchial epithelial cell (PBEC) cultures were grown from bronchial brushings 20 
obtained from mild asthmatics and non-asthmatic patients recruited from a specialist cough 21 
9 
 
clinic (19) and healthy participants recruited by advertisement. Demographic details are 1 
shown in Table 2.  2 
The study was approved by the appropriate Institutional Research Ethics Committees (details in 3 
online data repository). Written informed consent was gained from all participants prior to their 4 
involvement.  5 
 6 
 Bronchoscopy and sample processing 7 
All asthmatic participants were clinically stable at the time of bronchoscopy, and had an 8 
FEV1 >60% predicted. Bronchial biopsies and brushings were obtained from segmental 9 
airways using a standard techniques. Three biopsies from each participant (Belfast Cohort) 10 
were submitted for immunohistochemistry studies. Gene expression microarray analysis 11 
(and qPCR) was performed on fresh bronchial brushings (Leicester cohort). To investigate 12 
the functional role of TRPV1, PBEC cultures from bronchial brushings were cultured as 13 
described previously (20). These were obtained from mild asthmatic (n=4), non asthmatic 14 
patients with chronic cough (n=4) and healthy volunteers (n=4). 15 
Immunohistochemistry 16 
Twenty eight biopsies (10 healthy volunteer, 8 mild asthmatic and 10 severe asthmatic 17 
biopsies) were processed for immunohistochemistry (IHC) using local protocols as detailed 18 
in the online data repository. For TRPV1 and ER co-localisation experiments local protocols 19 
were employed as detailed in the online data repository. 20 
 21 
10 
 
Gene expression analysis 1 
Bronchial brushings and PBEC cultures 2 
Real-time PCR (qRT-PCR) analyses were performed using RNA from bronchial brushings using 3 
TaqMan® Gene Expression Assays (Applied Biosystems, Foster City, CA) as previously 4 
described (21). RNA was amplified (Ambion,) for Agilent (Santa Clara, CA) two color Whole 5 
Human Genome (WHG) 4x44k gene expression microarray analysis.   6 
 PBECs were trypsinised and total RNA extracted using the RNeasy Mini Kit (Qiagen, Hilden, 7 
Germany) and qRT-PCR performed using a 7300 Real Time PCR system (Applied Biosystems, 8 
Foster City, CA). More information including detail on GAPDH and TRPV1 forward and 9 
reverse primers is provided in the online data repository.  10 
Western Blotting 11 
Protein concentration was determined using BCA protein assay kit (Thermo Scientific, 12 
Wilmington, USA) and protein expression determined using a rabbit polyclonal TRPV1 13 
antibody (ab63083; Abcam, Cambridge, UK), at a dilution of 1:3000 followed by incubation 14 
for 1 h with the secondary antibody, HRP-labelled anti-rabbit (1:3000; Bio-Rad Laboratories, 15 
Hercules, CA, USA). More details provided in online data repository. 16 
TRPV1 agonists / antagonist experiments in PBECs 17 
Capsaicin is a selective TRPV1 agonist and in this study cultured PBECs were treated with either 10, 18 
25 or 50 µM capsaicin or control medium for 24 h and the concentration of IL-8 measured by ELISA 19 
(R & D Systems Europe Abingdon, UK). For the antagonist experiments, PBECs were pre-20 
treated for 20 min with 10 μM of the selective TRPV1 antagonist capsazepine. 21 
Patch clamp experiments 22 
11 
 
Whole-cell currents were recorded using borosilicate heat-polished patch pipettes (2-3 MΩ 1 
resistance when filled with the pipette solution) and an Axopatch 200B amplifier (Molecular 2 
Devices, Union City, CA, USA) interfaced to Digidata 1322A using the pClamp 9 software 3 
(Molecular Devices) as previously described by ourselves (22) and detailed in the online data 4 
repository.  5 
Data Analysis 6 
Data are presented as means ±SEM. For statistical analysis a one way ANOVA was performed 7 
with Bonferroni test for multiple comparisons. Kendall’s tau b statistical analysis was used to 8 
examine the trend in biopsy expression by participant group. Patch clamp data were 9 
analysed and plotted using Origin 8 (OriginLab, Northampton, MA, USA). A P value < 0.05 10 
was considered significant.  11 
 12 
RESULTS 13 
Confirmation of TRPV1 expression in cultured human bronchial epithelial cells.  14 
Gene expression for multiple members of the TRPV family including TRPV1 (but not TRPV5) 15 
was identified in PBECs from healthy controls (n=3) (Figure 1A). TRPV1 protein was detected 16 
at its expected molecular mass of 95 kDa by Western blotting in the same samples (Figure 17 
1B).   18 
Molecular identification and localisation (immunohistochemical expression) of TRPV1 in 19 
healthy and asthmatic epithelium 20 
Microarray 21 
12 
 
Using gene expression microarray analysis of bronchial brush samples from the Leicester 1 
cohort we found significantly greater levels of TRPV1 expression (median, IQR) in severe 2 
asthmatics (0.673, 0.452-0.761) compared to mild/moderate asthmatics (0.341, 0.167-0.538, 3 
p=0.008) and healthy volunteers (0.322, 0.155-0.410, p=0.004) (Figure 1C).  4 
Quantitative PCR.  5 
TRPV1 mRNA was detected in all of the epithelial brush samples. There was no difference in 6 
median (IQR) relative fold expression of TRPV1 mRNA calculated as Delta Delta CT values 7 
between groups: -1.262 (-3.598, 2.518), (, -2.523 (-4.040, 1.362) and -1.289 (-4.746, 1.624) in 8 
healthy volunteers, mild / moderate asthmatics and severe asthmatics respectively (see 9 
Figure E1 in online data repository) 10 
Immunohistochemistry  11 
Immunohistochemistry revealed bronchial epithelial expression of TRPV1 in healthy 12 
volunteers, mild/moderate asthmatics and severe asthmatics (Figures 2A, B and C, 13 
respectively). Dual labelling immunofluoresence confirmed the expression of TRPV1 on 14 
cytokeratin positive epithelial cells (Figures 3 A, B and C). We observed an intracytoplasmic 15 
distribution of the TRPV1 and to further characterise this we undertook additional 16 
experiments demonstrating immunohistochemistry staining of bronchial epithelial cells 17 
positive for TRPV1 (Figure 4A) and ER (Figure 4B) markers. Colocalisation was evident when 18 
the images were merged (Figure 4C).  19 
We observed greater TRPV1 expression in asthmatic epithelium compared to healthy 20 
subjects (Figure 5; p = 0.001).  21 
13 
 
Membrane current responses to TRPV1 agonist capsaicin 1 
Mean membrane capacitance of PBEC was 30.8±4.3 pF (n=6). In unstimulated cells, only 2 
small background currents could be recorded in the whole range of membrane potentials 3 
tested, from -100 to +140 mV (Figure 6A, left panel). The I-V relationship of the mean 4 
background current normalised by the membrane capacitance to account for some 5 
variations in cell size is shown in Figure 6B. It should be noted that composition of the 6 
external and pipette solutions was such that this facilitated isolation of cation currents but 7 
precluded activation of any potassium or calcium-dependent conductances. Capsaicin 8 
application (50 µM) caused rapid activation of large outwardly rectifying currents (Figure 6A, 9 
middle panel), which is the characteristic “biophysical” signature of TRPV1 channels. This 10 
effect was completely reversible upon capsaicin wash-out (Figure 6A, right panel). 11 
Corresponding I-V relationships are shown in Figure 6C. The capsaicin-induced currents 12 
reversed close to 0 mV indicating their non-selective cation nature. 13 
To investigate the time course of these responses, voltage ramps over the same range of 14 
potentials were applied at 10 s interval. Figure 7A shows a typical response to 50 µM 15 
capsaicin application consisting of rapid activation and desensitisation in the continuous 16 
presence of the agonist, which developed over 2-3 min. The I-V relationships which were 17 
measured in this experiment in control, at the peak response and after agonist wash-out are 18 
shown in Figure 7B (compare to I-V curves in Fig. 6C measured by voltage steps), while the 19 
mean results are summarised in panel C. The increase in current amplitude in response to 20 
capsaicin was significant (p=0.007). 21 
Membrane responses to reduction of external pH 22 
14 
 
Reduction of external pH from 7.4 to 6.4 activated inward and outward currents in cells from 1 
healthy patients which were partially inhibited by the addition of the selective TRPV1 2 
antagonist capsazepine (5 µM; Fig. 8A). The mean capsazepine-sensitive I-V relation (Fig. 8B 3 
n=4) was similar in profile to the capsaicin-dependent currents exhibiting strong outward 4 
rectification and reversal close to 0 mV. 5 
 6 
Functional expression of TRPV1 in cultured human primary bronchial epithelial cells 7 
Dose–dependent induction of IL-8 release from cultured human PBECs by capsaicin  8 
Dose-dependent induction of IL-8 release by capsaicin was observed within each study 9 
group although there was no significant difference in fold increase in IL-8 between asthmatic 10 
and non asthmatic groups which may relate to sample size (data not shown). The dose 11 
dependent increase in IL-8 release when data from all three groups was therefore pooled 12 
has been presented in figure 9A. When compared to basal a marginal 1.25-fold increase in 13 
IL-8 release was observed following incubation with 10 μM capsaicin with significant 14 
increases of  1.76-fold (p<0.01) and 2.15 -fold (p<0.001) compared to basal observed 15 
following incubation with 25 and 50 μM doses of capsaicin, respectively.  16 
To further test the specificity of the capsaicin effect, we used selective TRPV1 blocker 17 
capsazepine. Capsazepine significantly inhibited capsaicin-induced IL-8 release compared to 18 
25 μM capsaicin alone (p<0.001) and compared to 50 μM capsaicin alone (p<0.001). The 19 
data for n=9 individual experiments is shown in Figure9B. 20 
 21 
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 1 
DISCUSSION 2 
In this study we have shown for the first time that  TRPV1, which is primarily recognised as 3 
the major neuronal hot receptor (23, 24),  is expressed and functional in human bronchial 4 
epithelium. In primary bronchial epithelial cell cultures we have shown that pharmacological 5 
activation of the TRPV1 channel with capsaicin induces IL-8 release which can be attenuated 6 
by pre-treatment with the selective TRPV1 antagonist capsazepine.  7 
Interestingly, TRPV1 expression in the airway was increased in asthmatic subjects compared 8 
to healthy controls with a further increase in subjects with refractory asthma. Thus, over-9 
expression may have a role in symptoms associated with irritant exposure in asthma, 10 
particularly in patients with persisting symptoms despite treatment with high dose anti-11 
inflammatory therapy. Understanding the role of TRPV1 in refractory asthma may therefore 12 
identify a novel target for anti-inflammatory therapy in more severe disease. 13 
We believe that bronchial epithelial TRPV1 channels are ideally positioned to detect 14 
chemical and physical irritants (e.g. inflammatory mediators, environmental pollutants, acid 15 
pH and changes in temperature) in the airway lumen. To date, most of the focus has been 16 
on neuronal TRPV1 in the human airway (14, 25). However, TRPV1 expression has been 17 
reported in a variety of non-neuronal tissues and therefore we hypothesised that the airway 18 
responses to environmental stimuli might in part be regulated by the bronchial epithelial 19 
TRPV1 receptors. Recent studies in immmortalised airway epithelial cell lines provide some 20 
support for this (17, 26) although evidence in human disease is lacking. Here we provide in 21 
16 
 
vivo and ex vivo evidence of TRPV1 expression and function in human airway biopsies and 1 
cultured primary bronchial epithelial cells with specific relevance to refractory asthma. 2 
We observed an intracytoplasmic distribution of the receptor in bronchial epithelial cells  as 3 
observed in other cell types (27, 28). Our finding of TRPV1 staining in the endoplasmic 4 
reticulum is consistent with its functional role as a Ca2+ store release channel regulating 5 
intracellular Ca2+ homeostasis. Robust membrane current responses to the TRPV1 agonist 6 
capsaicin (Figs. 5 and 6) suggest strongly that plasmalemmal TRPV1 is also expressed and 7 
functional in PBEC. We also observed TRPV1 staining on a number of submucosal cells 8 
although the focus of this present study is confined to the bronchial epithelial expression. 9 
Previous studies from chronic coughers (14) and healthy subjects (15) have reported only 10 
sparse TRPV1 expression in the airway epithelium, although greater expression in the upper 11 
airway (29). Differences in tissue processing, antibodies used and clinical phenotype may 12 
explain the discrepancy. In our studies to evaluated the functional properties of TRPV1 on 13 
bronchial epithelium. we saw that PBECs responded to the TRPV1 agonist capsaicin with the 14 
release of pro-inflammatory mediators which was blocked by capsazepine, a TRPV1 selective 15 
antagonist. Capsaicin induced  IL-8 release has been previously observed in  both human 16 
esophageal (30) and human corneal epithelial cells (31) but not before in culturedPBECs. As 17 
IL-8 is known to induce and maintain neural sensitization (32, 33) our data provide a 18 
mechanistic link whereby activation of bronchial epithelial TRPV1 by environmental irritants 19 
or changes in airway pH or temperature (during exacerbations) may sensitize airway sensory 20 
neurones and contribute to the airway and cough hypersensitivity that characterises 21 
asthma.  22 
17 
 
Studies in immortalised respiratory cell lines suggest airway epithelial TRPV1 regulates cell 1 
apoptosis in response to environmental irritants (34).  Here, we provide the first evidence of 2 
a functional airway epithelial TRPV1 channel in primary cells. In the whole-cell patch clamp 3 
experiments on PBECs ourresults provide direct evidence for the presence of functional 4 
TRPV1 in the plasma membrane that can mediate membrane depolarisation and calcium 5 
influx; steps which are necessary for release of pro-inflammatory mediators (35). Both 6 
kinetics and voltage-dependent properties of capsaicin-induced currents in PBEC are 7 
consistent with TRPV1 biophysical features, such as slow activation/deactivation and strong 8 
outward rectification.  9 
TRP channels have the capacity to sense a vast range of stimuliand their role in airways 10 
disease is currently under intense investigation (1). In our immunohistochemical studies we 11 
have shown that TRPV1 is over expressed in the bronchial epithelium of asthmatics 12 
compared to healthy subjects and patients with refractory asthma express more epithelial 13 
TRPV1 than those with mild/moderate asthma. This was supported by our microarray 14 
analysis confirming increased expression of TRPV1 genes in the more severe asthmatics. 15 
Although on quantitative PCR, mRNA was not concordant with protein abundance, it has 16 
become increasingly clear that at the genomic level, mRNA expression does not consistently 17 
predict corresponding protein levels (36, 37). This may because of complex post-18 
transcriptional and translational modification and /or that different biological mRNA and 19 
protein degradation rates may affect correlation. Post translational modification of TRPV1 20 
has been described in experimentally induced tissue injury (38) and therefore may occur in 21 
the inflamed asthmatic airway.  22 
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While the vast majority of asthmatics respond to standard doses of current treatments (in 1 
particular corticosteroids), a proportion remain symptomatic despite treatment at GINA 2 
Step 4/5 and are considered to have difficult or treatment refractory asthma. Our finding 3 
that bronchial epithelial TRPV1 is over expressed in refractory (steroid-resistant) asthma 4 
suggests its activation may represent a novel pro-inflammatory pathway. Clinical trials of 5 
TRP receptor antagonists have been undertaken in other abnormal hypersensitive states 6 
including neuropathic pain and these drugs may prove effective in improving symptom 7 
control in asthma as well.  8 
Our findings suggest that the bronchial epithelium may sense and respond to environmental 9 
stimuli via TRPV1 activation. However it is not clear how bronchial epithelial cells signal to 10 
afferent sensory nerves. We suggest that release of sensitizing mediators such as IL-8 may 11 
be one such mechanism. Such mediators may enhance and augment neurogenic 12 
inflammation and nociceptive signalling. Therefore, pharmacological modulation of this 13 
receptor may be useful in the treatment of uncontrolled asthma. 14 
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receptor mRNA and protein in dorsal root ganglion neurons following local capsaicin 8 
treatment of the sciatic nerve in the rat. Neuroscience. 2012 Jan 10;201:320-30.  9 
 10 
 11 
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Table 1. Demographic characteristics of the Asthmatic Participants and Healthy Volunteers (Belfast 1 
and Leicester cohorts combined). Comparison with the Healthy Volunteer group †p<0.001, §p<0.001, 2 
llp<0.001, ** p<0.001, §§p<0.001, ‡ ‡ p<0.05, llllp<0.001. Comparison with Mild to Moderate 3 
Asthmatics: †p<0.001, ‡p=0.007, §p<0.001, ll p<0.001, ** p<0.001, †† p<0.0001, §§p<0.05, ***p<0.001. 4 
 Healthy 
Volunteers 
(n=22) 
Mild to Moderate 
Asthmatics 
(n=30) 
Severe Asthmatics 
(n=31) 
p Value 
Age (y), median (IQR)  30 (22 - 45) 29 (24 - 39) 48 (38 - 54)† <0.0001 
Sex, M/F 10/12 14/16 22/9 0.09 
Duration of asthma (y), 
mean  SD  
N/A 12 ±10 22±15‡ 0.007 
Atopy, (n) 11 21 23 0.16 
FEV1 (L/min), mean  SD  3.67±0.78 3.32±0.77 2.48±0.67
§ <0.0001 
FEV1 (%predicted), mean 
 SD  
102.8 11.9 93.516.0 75.9 16.9 ll  <0.0001 
FEV1/ FVC, mean  SD 82.1 9.8 75.9 10.6 64.6 11.1**
  <0.0001 
Inhaled steroid (n) 
BDP equivalent (µg), 
median (IQR) 
 
Maintenance systemic 
steroids (n) b  
 
 
0 
0 
 
 
0 
19 
400 (0 - 800) 
 
 
0 
31 
1600 (1200 - 1600)††  
 
 
15 (median dose 
prednisolone 5 mg 
[0 – 10 mg] plus 1 
subject maintenance 
intramuscular 
triamcinolone) 
 
<0.0001 
Theophylline, (n) 0 1 17 <0.0001 
Long-acting 2-agonists, 
(n) 
0 14 31 <0.0001 
Prior smoking 1 5 13 0.004 
25 
 
history (n) 
[pack years, median 
range] 
 
[4]  
 
[1, 1-10] 
 
[2.5, 1 – 20] 
Eosinophils (109/L), 
median (IQR) 
0.1 (0.07 - 0.21) 0.26 (0.14 - 0.45)‡‡  0.49 (0.25 - 0.74)§§  <0.0001 
IgE (kU/L), geometric 
mean (95% confidence 
interval) 
24.6 (13.3 - 45.8) 159.8 (89.8 - 
284.6)llll 
238.5 (136.2 - 
417.5)*** 
<0.0001 
 Calculated by ANOVA with Bonferroni’s Multiple Comparisons Test (parametric) or Kruskal-Wallis 1 
with Dunn’s Multiple Comparison Test (non-parametric) or t-test when only asthma groups 2 
compared or Chi-squared for categorical variables (sex, atopy, theophylline, long-acting 2-agonists, 3 
smoking history). 4 
 5 
6 
26 
 
Table 2. Demographic characteristics of the mild asthmatic, non-asthmatic cough and healthy 1 
volunteers recruited for experiments on cultured primary bronchial epithelial cells.  2 
 Healthy volunteers  
(n=4) 
mild asthmatics 
 (n=4) 
Non asthmatic 
coughers  
(n=4) 
P value 
Age, (y) 
Median (IQR) 
35.5 (21.3-43.8) 46.0 (39.3-56.8) 58.0(45.0-72.5) 0.05 
Sex, M/F 1/3 0/4 0/4 0.336 
Duration of cough 
(m) Mean ±SD 
N/A 49.5 (30.0) 57.5 (27.0) 0.950 
FEV1 (L/min) 
Mean ±SD 
3.45 (0.65) 2.52 (0.29) 2.3 (0.34)* 0.014 
FEV1, % pred 
Mean ±SD 
107.3 (10.59) 105.6 (15.23) 118.0 (21.28) 0.530 
FEV1/ FVC 
Mean ±SD 
86.6 (10.6) 82.73 (4.11) 80.2 (3.2) 0.446 
Atopy (n) 0 0 0 N/A 
Inhaled steroid (n) 0 4 0 N/A 
Prior smoking (n) 0 0 0 N/A 
Calculated by ANOVA with Bonferroni’s Multiple Comparisons Test (parametric) or Kruskal-Wallis 3 
with Dunn’s Multiple Comparison Test (non-parametric) or t-test when only cough groups compared 4 
or Chi-squared for categorical variables (gender). 5 
 6 
 7 
 8 
 9 
 10 
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 1 
Legends to Figures 2 
Figure 1: A. Molecular expression of TRPV channel subtypes in human primary bronchial 3 
epithelial cells. Conventional RT-PCR showing the expression of TRPV family subtypes 4 
including TRPV1 in PBECs from healthy controls (n=3) B. Expression of TRPV1 protein in 5 
PBECs. TRPV1 specific bands were observed at the molecular weight of 95 KDa in PBECs 6 
(lanes 2 to 4, upper panel). TRPV1 transfected HEK cells were used as a positive control (lane 7 
1, upper panel). β-Tubulin (lower panel) was used to ascertain equal loading (Abcam 6046). 8 
Results are representative of two independent experiments. C. Gene expression microarray 9 
analysis of bronchial brush samples from healthy, mild/moderate and severe asthmatics. 10 
Gene expression microarray analysis was performed on fresh bronchial brush samples from 11 
the Leicester cohort comprising severe asthmatics (n=12), mild/moderate asthmatics (n=16) 12 
and healthy subjects (n=8). TRPV1 was significantly elevated in severe asthma versus mild 13 
moderate asthma (* p=0.008) and healthy volunteers (** p=0.004).  14 
 15 
Figure 2 - Digital photographic images (A-D) of TRPV1 expression in JB4 sections from  (A)  16 
healthy control: only patchy or focal areas of low intensity epithelial expression;  (B) 17 
moderate asthmatic: majority of epithelial and submucosal cells  express antigen; (C) severe 18 
asthmatic: widespread and strong epithelial and submucosal cell expression. Sections 19 
incubated in the absence of antibodies showed no staining; a representative image is shown 20 
in (D). Representative immunohistochemistry shown at X 400 magnification 21 
 22 
28 
 
 Figure 3 – Confocal microscopy images (A-C) of double staining immunocytochemistry 1 
demonstrating localisation of TRPV1 channels in bronchial epithelium (healthy subject). 2 
Bronchial epithelial cells identified by positive red staining with the cytokeratin antibody 3 
AE1AE3 (A) were also positive for the TRPV1 (green) (B) and co-localisation was evident 4 
when the images were merged (yellow) (C).  Representative immunohistochemistry shown 5 
at X 400 magnification 6 
 7 
Figure 4: TRPV1 and ER colocalisation in human bronchial epithelial cells. Representative 8 
confocal microscopy images at X 40 magnification (A-C) showing immunohistochemistry 9 
staining of bronchial epithelial cells positive for TRPV1 (A) and ER (B) markers. Colocalisation 10 
was evident when the images were merged (C; orange/yellow). DAPI stained blue nuclei (C). 11 
Scale bar = 100 μm.  12 
 13 
 14 
Figure 5 Quantitative immunohistochemical epithelial expression for TRPV1 in bronchial 15 
biopsies. TRPV1 expression is increased in the bronchial epithelium of severe asthmatic 16 
patients. There was a trend to increased TRPV1 expression with severity of asthma (p=0.001, 17 
Kendall’s tau-B statistic).  18 
Figure 6. Whole-cell PBEC (healthy subject) membrane current responses to capsaicin 19 
application (50 µM) measured by voltage-steps. A. Superimposed current traces evoked by 1 20 
s voltage steps before, in the presence of, and after capsaicin wash-out, as indicated. Dotted 21 
line indicates zero-level current. B. Mean normalised I-V relationship of background current 22 
29 
 
(n=4). C. I-V relationships for the current amplitude measured at the end of each voltage 1 
step in the experiment illustrated in panel A. 2 
Figure 7. Time course of the capsaicin membrane current response. A. Current 3 
amplitude was monitored by applying voltage ramps from -100 to 140 mV at 10 s interval. 4 
Circles show current amplitude at 140 mV. B. The I-V relationships were derived from the 5 
ramps applied before, at the peak response and 3 min after wash-out of the drug as 6 
indicated. C. Mean normalised I-V relationships measured before (squares) and after 7 
(circles) capsaicin application (n=3). In each cell, current amplitude at 140 mV in control was 8 
normalised as 1.0. 9 
Figure 8. Whole-cell PBEC (healthy subject) membrane current responses to reduced 10 
external pH measured by voltage ramps. A. Superimposed current traces evoked by voltage 11 
ramps from -100 to 140 mV at 10 s interval in pH 7.4 and pH 6.4 (± capsazepine; 5µM) 12 
external solutions as indicated. The dotted line indicates zero-level current. B. Mean ± SEM  13 
I-V relationship (normalized for cell capacitance) of capsazepine-sensitive current (n=4). 14 
Figure 9. Capsaicin induces IL-8 release from human PBECs (asthmatic and non-asthmatic 15 
subjects). PBECs treated (24 hours) with 10, 25 or 50 μM capsaicin or control medium. 16 
Values are expressed as the mean release over basal ± SEM. A. Capsaicin-induced IL-8 17 
release ***p<0.001 compared to control; Kruskal-Wallis test with Dunn’s multiple 18 
comparison (n=12 individual experiments). B. Capsazepine inhibits capsaicin induced IL-8 19 
release from human PBECs. PBECs were pre-treated for 20 min with 10 μM capsazepine 20 
then with 10, 25 or 50 μM capsaicin or control medium with or without capsazepine. Values 21 
are expressed as mean release over basal ± SEM. Capsazepine significantly inhibited 22 
30 
 
capsaicin-induced IL-8 release  compared to 25 μM (*p<0.001) and and 50 μM (**p<0.001) 1 
capsaicin alone; one way ANOVA with Bonferroni’s multiple comparison test (n=9 individual 2 
experiments). 3 
 4 
 5 
 6 
 7 
 8 
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Study Subjects  
The studies were approved by the Research Ethics Committee of both Institutions (Belfast - 
Office of Research and Ethics Committee of Northern Ireland reference 06/NIR02/114 and 
09/NIR02/51, Leicester - Leicestershire, Northamptonshire, & Rutland Research Ethics Committee 
reference 04/Q2502/74). Written informed consent was gained from all participants prior to 
their involvement.  
Bronchial biopsies:  
Belfast Cohort: Participants with refractory asthma were recruited from the Belfast City 
Hospital where systematic evaluation protocols ensure patients have well-characterised 
refractory asthma. All participants had persisting symptoms despite treatment at Step 4 or 5 
of the GINA guidelines Global Initiative for Asthma (GINA) (E1). Mild to moderate asthmatic 
and normal participants were recruited by advertisement and had a clinical diagnosis of 
asthma with a current history of recurrent wheezing and response to asthma medication. 
Healthy volunteers had no history of asthma or persistent respiratory symptoms and normal 
lung function. All asthmatic participants were clinically stable on their usual medication at 
the time of bronchoscopy, and all participants had an FEV1 of greater than 60% predicted. 
Demographic details are shown in Table 1 of the main paper. 
Leicester cohort: For the gene expression studies, asthmatic subjects (n=36) and healthy 
volunteers (n=12) were recruited from respiratory clinics including the Leicester Difficult 
Asthma Clinic, from staff at Glenfield Hospital, and from the general population through 
advertisement (Leicester cohort). Subjects with asthma gave a suggestive history and had 
objective evidence of variable airflow obstruction as indicated by one or more of the 
following: (1) methacholine airway hyperresponsiveness (PC20 FEV1 < 8 mg/mL), (2) >15% 
improvement in FEV1 10 minutes after 200 g inhaled salbutamol, (3) peak expiratory flow 
(>20% maximum within-day amplitude from twice-daily peak expiratory flow measurements 
over a period of 14 days). Subjects underwent spirometry; allergen skin prick tests for 
Dermatophagoides pteronyssinus, dog, cat, grass pollen and Aspergillus fumigatus; a 
methacholine inhalation test using the tidal breathing method; and sputum induction using 
incremental concentrations of nebulized hypertonic saline (i.e., 3%, 4%, and 5%, each for 5 
min)(E2). Subjects with asthma also kept a diary card for 2 weeks prior to bronchoscopy, 
recording daytime and night-time symptoms, daily short-acting 2-agonist use and twice 
daily peak expiratory flow (PEF). Asthma severity was defined by British Guideline on the 
Management of Asthma treatment steps (mild = step 1, 2-agonist only; moderate = steps 2 
and 3, inhaled corticosteroid ≤800 mg beclomethasone equivalent per day ± long-acting 2-
agonist; severe = step 4 and 5) (E3). Of the 16 severe patients at step 4/5, 13 met the 
American Thoracic Society criteria for refractory asthma (E4). 
In both cohorts, all participants were current non-smokers with no upper or lower 
respiratory tract infection in the 6 weeks prior to their bronchoscopy. All asthmatic 
participants were clinically stable on their usual medication at the time of bronchoscopy. 
Demographic details for each cohort are shown in Table 1 in the main manuscript.  
 
 
Primary bronchial epithelial cell (PBEC) cultures: To investigate the functional role of TRPV1 
we performed a series of experiments on primary bronchial epithelial cell (PBEC) cultures 
from bronchial brushings obtained from mild asthmatic (n=4) and non asthmatic patients 
with chronic cough (n=4) referred to the Belfast City Hospital specialist cough clinic (E5). 
Healthy volunteers (n=4) were recruited by local advertisement. Demographic details for 
this cohort are shown in Table 2 in the main manuscript. 
Bronchoscopy and samples 
Bronchoscopy was performed using a standard technique. In brief, after intravenous 
sedation and local anaesthesia with topical lignocaine, bronchial biopsies and bronchial 
brushings were obtained from lobar / segmental airways. One biopsy from each participant 
was immediately placed in RNA preservative (RNAlater, Ambion, Austin, TX) and submitted 
for microarray analysis and qPCR and 3 biopsies placed immediately into dry acetone 
containing protease inhibitors (iodoacetamide and PMSF) and fixed overnight at -20C. 
Brushings were placed in RNAlater or Promocell™ medium containing 
penicillin/streptomycin and Primocin™ for cell culture (Promocell UK). PBECs were cultured 
using methods developed in our laboratory which resulted in homogenous cultures of basal 
epithelial cells (E6). 
For immunohistochemistry (IHC), biopsy samples were processed using local protocols. 
Twenty eight biopsies (10 healthy volunteer, 8 mild asthmatic and 10 severe asthmatic 
biopsies) were available for immunohistochemistry. Infiltration and embedding with JB4 
resin was performed as previously described (E7). Two m sections were cut from each 
biopsy. Endogenous peroxidise was blocked with 0.3% hydrogen peroxide. All sections were 
pressure cooked in 0.01M Tris-EDTA pH9.0 on full steam for 3 minutes for antigen retrieval. 
Sections were incubated with TRPV1 polyclonal antibody (1:200, Abcam), overnight at 4°C, 
then primary antibodies were detected by incubation for 30 min at RT in peroxidase-labelled 
EnVision anti-rabbit secondary antibody (Dako, Ely, UK) using 3,3’-diaminobenzidine (DAB; 
Dako, Ely, UK) as chromagen.   On selected tissue sections from this series, 
immunofluorescence was carried out to permit high resolution analysis of TRPV1 antigen 
distribution.  Sections were treated as for IHC and following incubation in a mix of TRPV1 
and a monoclonal antibody to the epithelial specific antibody AE1AE3 (1:50, Dako). Antigen 
binding sites were detected with a mixture of anti-mouse Alexa 568 and anti-rabbit Alexa 
488 (Invitrogen). Sections were counterstained with DAPI hardset mounting medium 
(Vector). All fluorescently stained slides were assessed and digital fluorescent images 
acquired with a Leica DFC350 FX digital camera and processed using Leica FW4000 software. 
Immunostained sections were evaluated by two independent persons, following which 
results were discussed and consensus scoring applied to any conflicting results. A 4-point 
scoring system was used: 0 - no detectable expression in epithelium or submucosa; 
1 - patchy or focal areas of low intensity epithelial expression, not all cells expressing 
positivity for protein, scattered positivity in submucosa; 2 - moderate / majority of epithelial 
and submucosal cell expression; 3 - widespread and strong epithelial and submucosal cell 
expression.  
TRPV1 and ER colocalisation in human bronchial epithelial cells.  
Human bronchial epithelial cells were grown on coverslips and fixed in 4% 
paraformaldehyde (PFA) for 30 minutes at RT. Cells were briefly washed in Phosphate 
Buffered Saline (PBS) before being permeabilised with 0.1% Triton X-100 in PBS for 20 
minutes at RT. Cells were blocked with 10% Bovine Serum Albumin (BSA) in PBS for 1 hour at 
RT and incubated with primary antibodies, mouse monoclonal anti-KDEL (1:500), ER marker 
and rabbit polyclonal anti-VR1 (1:200), TRPV1 marker (AB12223 and Ab63083 respectively; 
Abcam, Cambridge, UK) overnight at 40C, followed by incubation for 1 hour at RT with 
secondary antibodies, Alexa Fluor goat anti-mouse 488 (1:500; Invitrogen) and Alexa Fluor 
goat anti-rabbit 568 (1:500; Invitrogen). Cell nuclei were stained using Vectashield mounting 
medium containing DAPI (Vector Labs, Peterborough, UK). Staining was visualised and 
images captured using Nikon EZ-C1 confocal system running C1 acquisition software (Nikon 
UK Ltd. Surrey, UK) at x40 magnification. 
 
Gene expression analyses 
RNA was isolated from homogenized bronchial biopsies and real-time PCR (qPCR) was 
performed as described previously  (E8).  TaqMan® Gene Expression Assays (Applied 
Biosystems, Foster City, CA) were purchased and conducted per manufacturer’s instructions 
for TRPV1. RNA was amplified (Ambion,) for Agilent (Santa Clara, CA) two color Whole 
Human Genome (WHG) 4x44k gene expression microarray analysis.  Universal Human 
Reference RNA (Stratagene, La Jolla, CA) was used for the reference channel.  Probe 
intensities were transformed as log2 ratios of test and reference channels calculated by the 
Agilent Feature Extraction software, protocol GE2-v5_95 (Agilent).  Flagged outliers were 
not included in any subsequent analyses. All gene expression analyses and plotting were 
performed using the R Project software package, version 2.10.1 (refer to http://www.R-
project.org). 
 
Quantitative Real-Time PCR  
Bronchial brushings 
Real-time PCR (qRT-PCR) analyses were performed using RNA from homogenized bronchial 
brushings (36 subjects; 10 HV, 16 MA  and 15 SA) using TaqMan® Gene Expression Assays 
(Applied Biosystems, Foster City, CA) as previously described. The delta-delta Ct method was 
used to calculate relative fold expression with GAPDH as housekeeping gene  
PBEC cultures 
 PBECs were trypsinised and cells lysed using Qiagen RLT buffer (Qiagen, Hilden, Germany) 
before homogenisation using QIAshredders (Qiagen, Hilden, Germany). RNA was then 
extracted using the RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA concentration was 
measured with the nanodrop spectrophotometer (Thermo Scientific, Wilmington, USA) and 
1μg RNA was used to synthesise cDNA using the high capacity cDNA reverse transcription kit 
(Applied Biosystems, Foster City, CA). PBEC cDNA was mixed with Power Sybr Green PCR 
master mix (Applied Biosystems, Foster City, CA) and either GAPDH or TRPV1 forward and 
reverse primers (Table E1). The following PCRs were performed in a 7300 Real Time PCR 
system (Applied Biosystems, Foster City, CA). Melting curves showed formation of only one 
gene product per primer pair. Normalisations and calibrations of the data from all studies 
were performed with the 2-ΔΔCT method as described in Applied Biosystems User Bulletin No. 
2 (P/N 4303859) (27). Delta CT was calculated as target gene expression (CT) minus internal 
housekeeping control, GAPDH gene expression (CT). Human Universal Reference RNA 
(Clontech, P/N 639654) was prepared as cDNA and utilised as plate calibrators. DeltaDelta 
CT was calculated as sample Delta CT minus plate calibrator Delta CT. GAPDH and TRPV1 
forward and reverse primers are detailed in table E1 below.  
 Western Blotting 
PBECs were collected and snap frozen, homogenised and lysed in RIPA buffer supplemented 
with protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). Protein 
concentration was determined using BCA protein assay kit (Thermo Scientific, Wilmington, 
USA). 30μg of total protein was separated on the 8% SDS-Polyacrylamide gel by 
electrophoresis and transferred to Hybond-P PVDF membrane (GE Healthcare Life Sciences, 
Buckinghamshire, UK). The membrane was blocked for 30 min in 3% BSA/ PBS and then 
probed overnight in 3% BSA/PBS with a rabbit polyclonal TRPV1 antibody (ab63083; Abcam, 
Cambridge, UK), at a dilution of 1:3000. Followed by incubation for 1 h with the secondary 
antibody, HRP-labelled anti-rabbit (1:3000; Bio-Rad Laboratories, Hercules, CA, USA). Images 
were obtained using UVP bioimager (UVP, Cambridge, UK). Benchmark Pre-stained protein 
standards (Invitrogen, Paisley, UK) were used to determine molecular mass. 
 
Patch clamp experiments 
Whole-cell currents were recorded using borosilicate heat-polished patch pipettes (2-3 MΩ 
resistance when filled with the pipette solution) and an Axopatch 200B amplifier (Molecular 
Devices, Union City, CA, USA) interfaced to Digidata 1322A using the pClamp 9 software 
(Molecular Devices). Series resistance was compensated by about 70%. Holding potential 
was -40 mV. Steady-state current-voltage (I-V) relationships were measured by applying 
either voltage steps (test potentials from -100 to +140 mV with a 20 mV increment) or slow 
voltage ramps from -100 to +140 mV. To monitor the time course of TRPV1 activation by 
capsaicin, the voltage ramps were applied at 10 s interval. The I-V curves obtained by the 
voltage ramp and step protocols were similar confirming steady-state channel activity at 
each test potential when ramps were used. 
For experiments involving the addition of capsaicin the  external solution contained (mM): 
NaCl 120, glucose 12, HEPES 10, pH 7.4 (adjusted with NaOH). Pipette solution contained 
(mM): CsCl 80, MgATP 1, creatine 5, GTP 1, D-glucose 5, HEPES 10, BAPTA 10, CaCl2 4.6 
([Ca2+]i=100 nM), pH 7.4 (adjusted with CsOH). For experiments involving altered pH the 
external solution contained (mM): NaCl 150, CsCl 6, MgCl2 1.3, CaCl2 2, Glucose, 5; HEPES, 
10; pH7.4 or 6.4 with Tris. Pipette solution contained (mM): CsOH 130, D Gluconic Acid 120, 
MgCl2 1, EGTA 0.5 ([Ca
2+]i= 30 nM), pH 7.2 with Tris. 
IL-8 ELISA 
IL-8 concentrations were measured from aliquots of culture medium taken 24 h following 
treatment with capsaicin (Enzo Life Sciences, Exeter, UK) using a commercial ELISA kit from 
R & D Systems Europe (Abingdon, UK). 
Data Analysis 
Data are presented as means ±SEM. For statistical analysis a one way ANOVA was 
performed with Bonferroni test for multiple comparisons. Kendall’s tau b statistical analysis 
was used to examine the trend in biopsy expression by participant group. Patch clamp data 
were analysed and plotted using Origin 8 (OriginLab, Northampton, MA, USA). A P value < 
0.05 was considered significant.  
RESULTS 
Real time PCR (qRT PCR) analysis of fresh bronchial brush samples from the Leicester 
cohort comprising healthy, mild/moderate and severe asthmatics. Analysis was performed 
on fresh bronchial brush samples from the Leicester cohort comprising severe asthmatics 
(n=15), mild/moderate asthmatics (n=16) and healthy subjects (n=10). TRPV1 mRNA was 
detected in all of the epithelial brush samples. There was no difference in median (IQR) 
relative fold expression of TRPV1 mRNA calculated as Delta Delta CT values between groups: 
-1.262 (-3.598, 2.518), (, -2.523 (-4.040, 1.362) and -1.289 (-4.746, 1.624) in healthy 
volunteers, mild / moderate asthmatics and severe asthmatics respectively (see figure E1 
below). 
 
 
Online Figure Legend  
Figure E1: Real time PCR (qRT PCR) expression of TRPV1 in fresh bronchial epithelial brush 
samples from healthy volunteers, mild/moderate asthmatics and severe asthmatics. 
Analysis of fresh bronchial brush samples from the Leicester cohort comprising healthy 
(n=10), mild/moderate (n=16) and severe asthmatics (n=15). Data presented as median 
(IQR) relative fold expression of TRPV1 mRNA calculated as delta delta CT values.  
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Table E1. Forward and reverse primers for TRPV1 and GAPDH 
Primer name Forward Reverse Size (bp) 
TRPV1 GCCTGGAGCTGTTCAAGTTC GCCTGAAACTCTGCTTGACC 452 
TRPV2 CCAGCTCTCCAGTTTTCAGG GTTCAGCACAGCCTTCATCA 365 
TRPV3 TTCCTCATGCACAAGCTGAC TGCGCTTCACAAAGTCATTC 490 
TRPV4 CCCGTGAGAACACCAAGTTT GAAGAGCGTAATGACCTCGC 374 
TRPV5 TTGCTCAGTTGCTGTCATCC GCTCCTCTTTGTCGAACGTC 307 
TRPV6 TCACTTCGCTTCCTGGAACT ACACGCTTTCCACAAGCTCT 401 
GAPDH GCTCTCTGCTCCTCCTGTTC AAATCCGTTGACTCCGACC 100 
 
Source:  Invitrogen 
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 Online Repository Figure E1. Real time PCR (qRT PCR) expression of TRPV1 in fresh 
bronchial epithelial brush samples from healthy volunteers, mild/moderate asthmatics and 
severe asthmatics. 
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